Process for the preparation and activation of susbstances and a means of producing same

ABSTRACT

The present invention relates to a process for the preparation and activation of a substance and a means for producing the activated substance. In particular, the invention relates to a method of treating a disease in a subject in need of such treatment, comprising the step of administering a substance or active agent which comprises one or more components which have been agitated such that a harmonic of between 20 to 50 Hz has been produced, in an amount effective to treat said disease, with the proviso that the disease is not an airway disorder.

FIELD OF THE INVENTION

The present invention relates to a process for the preparation andactivation of a substance and a means for producing the activatedsubstance. In particular, the invention relates to a process ofpreparing a substance, wherein the substance is activated such that theefficacy and/or bioavailability of the substance is increased byagitating the substance or one or more components of the substance sothat a specific harmonic is obtained. In one embodiment the activatedsubstance is capable of regulating the cytochrome P₄₅₀ pathways andthereby overcoming or at least alleviating conditions associated withreactive oxygen species (ROS).

BACKGROUND OF THE INVENTION

It is well appreciated by those skilled in the art that many substancesincluding food, therapeutics, agricultural chemicals includingpesticides, herbicides, and other industrial chemicals have limitedefficacy in use. This is despite these substances having been used, insome instances, for thousands of years. Many foodstuffs, for example,are known to be poorly digested and/or absorbed by the gastrointestinaltract. Also the efficacy and/or bioavailability of therapeutics haveoften proven disappointing even though these materials have provenuseful in in vitro systems. More concerning is that certain foodstuffand therapeutics may even have harmful effects attributed to them.

In an attempt to overcome or at least alleviate some of these problems anumber of researchers have worked on improving particular substances ormodifying the biological systems being affected. One area that hasreceived some attention recently has been the role of the cytochromeP₄₅₀ enzyme system and in particular the protective effects this systemprovides against reactive oxygen species (ROS).

The production of ROS, including free radicals and free radical productsis known to be deleterious. Further, ROS are also produced byone-electron peroxidase oxidations to cation radicals, stabilisation ofthe ROS generator, CYP2E1. ROS are known to be cytotoxic and causeinflammatory disease, including tissue necrosis, arthritis and deficitsin energy metabolism (Manual et al, 2000).

Free radicals are formed in the body through unpaired electrons formedwhen there is no apparent enzyme synthesised by the liver to match thecorresponding electron of an atom of certain substances in the body.These substances are often particles of synthetic chemical compounds forwhich the human enzyme system has not yet developed enzymes to enablecomplete detoxification via the liver and excretory organs, for examplethe bowel, kidneys and skin. The free radicals formed in this mannerroam free in the body and contribute to inflammation and other harmfulcellular changes in a variety of tissues, for example in the tendons,muscles, ligaments and bones (Lall et al, Indian Journal of ExperimentalBiology. 37 (2): 109-16, February 1999) Demineralisation is alsoconsidered to contribute to free radical pathology (Lall et al, supra);thus resulting in arthritis, inflammatory joint and soft tissue diseaseand osteoporosis.

Trace elements including zinc, magnesium and selenium are some of theelements involved in antioxidant defence mechanisms. Inadequate intakeof these nutrients have been associated with ischemic heart disease,arthritis, stroke and cancer, where pathogenic role of free radicals issuggested (Lall et al, supra).

Whilst certain vitamin and mineral supplements are known, as arespecific treatments for the remedy of certain of the medical conditionsmediated by free radicals and ROS, there is no formulation availablecapable of preventing and treating effectively a wide range of medicalconditions mediated by free radicals.

Further, the role played by nutrition in protecting against the effectsof ROS have only recently been acknowledged. The biological antioxidantdefence system includes glutathione reductase,glutathione-s-transferase, glutathione peroxidase, phospholipidhydroperoxide glutathione peroxidase, superoxide dismutase (SOD) whichis a selenium dependent enzyme and catalase, together with theantioxidant vitamins C and E. The individual components of this systemare utilised in various physiological and protective processes andtherefore require replenishment from the diet. Other components of thediet including carbohydrates, proteins and lipids are known to beimportant for maintaining the levels of various enzymes required inbody's defence system providing protection against toxins for exampleheavy metals such as lead which can contribute to loss of bone density(Zerwekh and Pak, 1998).

Accordingly, there is a need to improve a range of substances so thatincreased efficiency, efficaciousness and/or bioavailability isproduced. Also there is a need to provide foodstuff and therapeuticsthat are capable of regulating the cytochrome P₄₅₀ pathways such thatthe host defence mechanisms are able to counteract the effects of ROS.

The applicant has now surprisingly found that substances, may beenhanced with respect to efficacy and/or bioavailability by usingspecific agitation methods which produce particular harmonics.

Moreover, certain substances produced by the methods of the presentinvention are capable of regulating the cytochrome P₄₅₀ pathwaysallowing the effective prevention and/or treatment of disorders mediatedat least in part by free radicals.

SUMMARY OF THE INVENTION

A first aspect of the invention provides an active substance, whereinsaid substance has been agitated such that a harmonic of between 20 to50 Hz has been produced.

A second aspect of the invention provides a process of preparing anactive substance comprising the step of agitating said substance suchthat a harmonic of between 20 to 50 Hz is produced.

A third aspect of the invention provides a device for preparing anactive substance comprising a container and a agitator, wherein saiddevice is capable of producing in a substance a harmonic of between 20to 50 Hz.

A fourth aspect of the invention provides a method of treating a diseasein a subject in need of such treatment, comprising the step ofadministering a substance or active agent which comprises one or morecomponents which have been agitated such that a harmonic of between 20to 50 Hz has been produced, in an amount effective to treat saiddisease.

A fifth aspect of the invention provides a substance or active agentuseful for treating a disease in a subject in need of such treatment,comprising ascorbic acid, magnesium and selenomethionine and apharmaceutically acceptable carrier, wherein at least one component hasbeen agitated such that a harmonic of between 20 to 50 Hz has beenproduced, together in an amount effective to treat said disease.

A sixth aspect of the invention provides a method of producing asubstance or active agent useful for treating a disease in a subject inneed of such treatment, said formulation or composition comprisingvitamins, trace elements and probiotic bacteria said method comprisingthe step of agitating at least one component of said substance or activeagent such that a harmonic of between 20 to 50 Hz is produced.

The foregoing and other aspects of the present invention are explainedin greater detail in the specification below.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 shows energy of particles produced in a vortex in an isotropic.

FIG. 2 shows energy gradient of produced rotons.

FIG. 3 shows the two competing processes of the apparatus contributingto the crossover behaviour in the roton energy.

FIG. 4 shows a diagrammatic representation of process.

DETAILED DESCRIPTION OF THE INVENTION

The practice of the present invention employs, unless otherwiseindicated, conventional food production techniques, chemistry andpharmacology within the skill of the art. Such techniques are well knownto the skilled worker, and are explained fully in the literature. See,eg., Coligan, Dunn, Ploegh, Speicher and Wingfield “Current protocols inProtein Science” (1999) Volume I and II (John Wiley & Sons Inc.); andBailey, J. E. and Ollis, D. F., Biochemical Engineering Fundamentals,McGraw-Hill Book Company, NY, 1986.

Before the present methods are described, it is understood that thisinvention is not limited to the particular materials and methodsdescribed, as these may vary. It is also to be understood that theterminology used herein is for the purpose of describing particularembodiments only, and is not intended to limit the scope of the presentinvention which will be limited only by the appended claims. It must benoted that as used herein and in the appended claims, the singular forms“a,” “an,” and “the” include plural reference unless the context clearlydictates otherwise. Thus, for example, a reference to “a substance”includes a plurality of such substances, and a reference to “anharmonic” is a reference to one or more harmonics, and so forth. Unlessdefined otherwise, all technical and scientific terms used herein havethe same meanings as commonly understood by one of ordinary skill in theart to which this invention belongs. Although any materials and methodssimilar or equivalent to those described herein can be used to practiceor test the present invention, the preferred materials and methods arenow described.

All publications mentioned herein are cited for the purpose ofdescribing and disclosing the protocols, reagents and vectors which arereported in the publications and which might be used in connection withthe invention. Nothing herein is to be construed as an admission thatthe invention is not entitled to antedate such disclosure by virtue ofprior invention.

The present invention relates to a process of activation. The terms“active” and “activation” as used herein with reference to the“substance” means the ability to produce a substance that has enhancedeffects. For example, with respect to chemicals such as herbicides andpesticides, the term “activation” means that these are more efficaciousin that they kill plants or pests more effectively than the comparableamount of unactivated herbicide or pesticide. Activation with respect tofoodstuff and therapeutics means that they are more efficacious and/orbioavailable when compared to the same amount of unactivated foodstuffor therapeutic. In one embodiment the “activated” substance is capableof regulating the cytochrome P₄₅₀ pathways and thereby overcoming or atleast alleviating conditions in a subject associated with reactiveoxygen species (ROS).

The term “subject” as used herein refers to any animal or plant species.However, the term “subject” depends upon the substance of the inventionbeing activated and its end use. For example, if the substance beingactivated is a herbicide then the “subject” is a plant. If the substancebeing activated is a pesticide then the “subject” is an invertebrate orvertebrate pest. Some of methods of the present invention areparticularly useful in the treatment of warm-blooded vertebrates. Thus,in a preferred embodiment, the “subject” of the invention concernsmammals and birds.

In one preferred embodiment the present invention is concerned primarilywith the treatment of human subjects, but can also be employed for thetreatment of other mammalian subjects, such as dogs, cats, livestock,primates and horses, for veterinary purposes.

Thus, provided is the treatment of mammals such as humans, as well asthose mammals of economical importance and/or social importance tohumans, for instance, carnivores other than humans (such as cats anddogs), swine (pigs, hogs, and wild boars), ruminants (such as cattle,oxen, sheep, giraffes, deer, goats, bison, and camels), and horses. Alsoprovided is the treatment of birds, including the treatment of thosekinds of birds that are endangered, kept in zoos, as well as fowl, andmore particularly domesticated fowl, eg., poultry, such as turkeys,chickens, ducks, geese, guinea fowl, and the like, as they are also ofeconomical importance to humans. Thus, provided is the treatment oflivestock, including, but not limited to, domesticated swine (pigs andhogs), ruminants, horses, poultry, and the like.

The term “substance” as used herein is any substance which can benefitfrom being activated. For example, a substance may be a foodstuff, achemical or a component of a chemical or foodstuff. Preferably thesubstance includes an active agent. As used herein, the term “activeagent” refers to an agent which possesses useful properties such as atherapeutic or prophylactic activity in vivo, or herbicidal orpesticidal activity, or nutritional property. The term “active agent”also includes other (non-active) substances, which may, for example, beadministered together with or combined with the active agent to aidapplication and/or administration. Examples of suitable active agentsinclude proteins, such as hormones, antigens, and growth factors;chemicals such as herbicides, pesticides, dyes, and anti-oxidants,vitamins and minerals; probiotic bacteria; nucleic acids; and smallermolecules, such as antibiotics, steroids, and decongestants.

The active agent can include organic molecules such as a drug, peptide,protein, carbohydrate (including monosaccharides, oligosaccharides, andpolysaccharides), nucleoprotein, mucoprotein, lipoprotein, syntheticpolypeptide or protein, or a small molecule linked to a protein,glycoprotein, steroid, nucleic acid (any form of DNA, including cDNA, orRNA, or a fragment thereof), nucleotide, nucleoside, oligonucleotides(including antisense oligonucleotides), gene, lipid, hormone, vitamin,including vitamin C and vitamin E, minerals and elements such asmagnesium, selenium or combinations thereof.

Representative therapeutic active agents include antioxidants,chemotherapeutic agents, steroids (including retinoids), hormones,antibiotics, antivirals, antifungals, antiproliferatives,antihistamines, anticoagulants, antiphotoaging agents, melanotropicpeptides, nonsteroidal and steroidal anti-inflammatory compounds. Othernon-limiting examples of active agents include anti-infectives such asnitrofurazone, sodium propionate, antibiotics, including penicillin,tetracycline, oxytetracycline, chlorotetracycline, bacitracin, nystatin,streptomycin, neomycin, polymyxin, gramicidin, chloramphenicol,erythromycin, and azithromycin; sulfonamides, including sulfacetamide,sulfamethizole, sulfamethazine, sulfadiazine, sulfamerazine, andsulfisoxazole, and anti-virals including idoxuridine; antiallergenicssuch as antazoline, methapyritene, chlorpheniramine, pyrilamineprophenpyridamine, hydrocortisone, cortisone, hydrocortisone acetate,dexamethasone, dexamethasone 21-phosphate, fluocinolone, triamcinolone,medrysone, prednisolone, prednisolone 21-sodium succinate, andprednisolone acetate; desensitizing agents such as ragweed pollenantigens, hay fever pollen antigens, dust antigen and milk antigen;decongestants such as phenylephrine, naphazoline, and tetrahydrazoline;miotics and anticholinesterases such as pilocarpine, esperinesalicylate, carbachol, diisopropyl fluorophosphate, phospholine iodide,and demecarium bromide; parasympatholytics such as atropine sulfate,cyclopentolate, homatropine, scopolamine, tropicamide, eucatropine, andhydroxyamphetamine; sympathomimetics such as epinephrine; sedatives andhypnotics such as pentobarbital sodium, phenobarbital, secobarbitalsodium, codeine, (α-bromoisovaleryl)urea, carbromal; psychic energizerssuch as 3-(2-aminopropyl)indole acetate and 3-(2-aminobutyl)indoleacetate; tranquilizers such as reserpine, chlorpromayline, andthiopropazate; androgenic steroids such as methyl-testosterone andfluorymesterone; estrogens such as estrone, 17-β-estradiol, ethinylestradiol, and diethyl stilbestrol; progestational agents such asprogesterone, megestrol, melengestrol, chlormadinone, ethisterone,norethynodrel, 19-norprogesterone, norethindrone, medroxyprogesteroneand 17-β-hydroxy-progesterone; humoral agents such as theprostaglandins, for example PGE₁, PGE₂ and PGF₂; antipyretics such asaspirin, sodium salicylate, and salicylamide; antispasmodics such asatropine, methantheline, papaverine, and methscopolamine bromide;antimalarials such as the 4-aminoquinolines, 8-aminoquinolines,chloroquine, and pyrimethamine, antihistamines such as diphenhydramine,dimenhydrinate, tripelennamine, perphenazine, and chlorphenazine;cardioactive agents such as dibenzhydroflume thiazide, flumethiazide,chlorothiazide, and aminotrate; nutritional agents such as vitamins,natural and synthetic bioactive peptides and proteins, including growthfactors, cell adhesion factors, cytokines, and biological responsemodifiers.

Representative herbicidal active agents include any active agentpreviously used as an agent for controlling or eradicating plants.Non-limiting examples of herbicides are 2,4-D (WEEDAR™); 2,4-DB; DCPA(Dacthal™); DSMA (ARSONATE™; EPTC (EPTAM™); EPTC (ERADICANE™); MCPA(RHONOX™); MCPB (THISTROL™); MSMA (ANSAR™); acetochlor (HARNESS™);acetochlor (SURPASS™); acifluorfen (BLAZER™); alachlor (LASSO™); ametryn(EVIK™); amitrole (AMITROL-T™); asulam (ASULOX™); atrazine (AATREX™);azafenidin (MILESTONE™); benefin (BALAN™); bensulfuron (LONDAX™);bensulide (PREFAR™); bentazon (BASAGRAN™); bromacil (HYVAR-X™);bromoxynil (BUCTRIL™); butylate (SUTAN™); carfentrazone-ethyl (AIM™);chloramben (AMIBEN™); chlorimuron-ethyl (CLASSIC™); chlorpropham(FURLOE™); chlorsulfuron (GLEAN™); clethodim (PRISM™); clethodim(SELECT™); clomazone (COMMAND™); clopyralid (STINGER™); cloransulam(FIRST-RATE™); cyanazine (BLADEX™); cycloate (RO-NEET™); cycloxydim(FOCUS™); desmedipham (BETANEX™); dicamba (BANVEL™); dichlobenil(CASORON™); diclofop (HOELON™); diethatyl (ANTOR™); difenzoquat(AVENGE™); diflufenzopyr (DISTINCT™); dimethenamid (FRONTIER™); diquat(DIQUAT™); diuron (KARMEX™); endothall (DESICATE™); ethalfluralin(CURBIT™); ethalfluralin (SONALAN™); ethametsulfuron (MUSTER™);ethofumesate (NORTRON™); fenoxaprop-ethyl (BUGLE™); fenoxaprop-ethyl(OPTION II™); fluazifop-P (FUSILADE DX™); flucarbazone-sodium (MKH6562™); flufenacet (AXIOM™); flumetsulam (BROADSTRIKE™); flumiclorac(RESOURCE™); flumioxazin (V-53482™); fluometuron (COTORAN™); fluroxypyr(STARANE™); fomesafen (FLEXSTAR™); fomesafen (REFLEX™); glufosinate(RELY™); glyphosate (ROUNDUP™); halosulfuron (PERMIT, SEMPRA™);haloxyfop (GALANT™); hexazinone (VELPAR™); imazameth (CADRE™);imazamethabenz (ASSERT™); imazamox (RAPTOR™); imazaquin (SCEPTER™);imazethapyr (PURSUIT™); isoxaben (GALLERY™); isoxaflutole (BALANCE™);lactofen (COBRA™); linuron (LOROX™); methazole (PROBE™); metolachlor(DUAL™); metribuzin (LEXONE™); metribuzin (SENCOR™); metsulfuron(ALLY™); molinate (ORDRAN™); napropamide (DEVRINOL™); naptalam (ALANA™);nicosulfuron (ACCENT™); norflurazon (SOLICAM™); oryzalin (SURFLAN™);oxadiazon (RONSTAR™); oxasulfuron (DYNAM™); oxyfluorfen (GOAL™);paraquat (GRAMOXONE EXTRA™); pebulate (TILLAM™); pelargonic acid(SCYTHE™); pendimethalin (PENTAGON™); pendimethalin (PROWL™);phenmedipham (SPIN-AID™); picloram (TORDON™); primisulfuron (BEACON™);prodiamine (BARRICADE™); prometryn (CAPAROL™); pronamide (KERB™);propachlor (RAMROD™); propanil (STAMPEDE™); prosulfuron (PEAK™); pyrazon(PYRAMIN™); pyridate (LENTAGRAN™); pyridate (TOUGH™); pyrithiobac(STAPLE™); quinclorac (FACE™); quizalofop (ASSURE™); rimsulfuron(MATRIX, SHADEOUT™); sethoxydim (POAST™); siduron (TUPERSAN™); simazine(PRINCEP™); sulfentrazone (AUTHORITY™); sulfometuron (OUST™); sulfosate(TOUCHDOWN™); sulfosulfuron (MON™); tebuthiuron (SPIKE™); terbacil(SINBAR™); thiazopyr (VISOR, MANDATE™); thifensulfuron (PINNACLE™);thiobencarb (BOLERO™); tralkoxydim (ACHEIVE™); triallate (FAR-GO™);triasulfuron (AMBER™); tribenuron (EXPRESS™); triclopyr (GARLON™);triclopyr (GRANDSTAND™); trifluralin (TREFLANT™); triflusulfuron(UPBEET™) and vernolate (VERNAM™).

Representative pesticidal active agents include 1,2-Dichloropropane;1-Naphthaleneacetamid; 1-Naphthylacetic Acid; 2,4,5-T Acid; 2,4,5-TAmine Salts; 2,4,5-T Esters; 2,4-D-Acid; 2,4-DB Butoxyethyl ES; 2,4-DBDimethylamine; ABAMECTIN™; ACEPHATE™; ACIFLUOREN™; ACIFLUORFEN™;ACROLEIN™; ALACHLOR™; ALDICARB™; ALDOXYCARB™; ALDRIN™; AMETRYN™;AMINOCARB™; AMITRAZ™; AMITROLE™; ANCYMIDOL™; ANILAZINE™; Arsenic Acid;Asulam, Sodium; ATRAZINE™; AZIMSULFURON™; AZINPHOS-ME™; BARBAN™;BENALAXYL™; BENDIOCARB™; BENEFIN™; BENODANIL™; BENOMYL™; BENSULFURONME™; BENSULIDE™; BENTAZON™; BIFENOX™; BIFENTHRIN™; BROMACIL™; BromoxynilButyrate; BROMOXYNIL™; OCTANOATE™; BUTACHLOR™; Butylate; CAPTAFOL™;CAPTAN™; CARBARYL™; CARBENDAZIM™; CARBOFURAN™; Carbon Disulfide;CARBOPHENOTHION™; CARBOXIN™; CDAA; CHLORAMBEN™; CHLORBROMURON™;CHLORDANE™; Chlordimeform; Chlordimeform HCl; CHLORETHOXYFOS™;CHLORIDAZON™; CHLOROBENZILATE™; CHLORONEB™; CHLOROPICRIN™;CHLOROTHALONIL™; CHLOROXURON™; CHLORPROPHAM™; CHLORPYRIFOS™;Chlorpyrifos-Methyl; CHLORSULFURON™; CHLOZOLINATE™; CINMETHYLIN™;CLOFENTEZINE™; CLOMAZONE™; CLOPYRALID™; CRYOLITE™; CYANAZINE™;CYCLOATE™; CYFLUTHRIN™; CYHALOTHRIN™; CYHEXATIN™; CYMOXANIL™;CYPERMETHRIN™; CYROMAZINET™; DAMINOZIDE™; DAZOMET™; DBCP™; DCNADICLORAN™; DDD™; DDE™; DDT™; DEMETON™; DESMEDIPHAM™; DI-ALLATE™;DIAZINON™; DICAMBA™; DICHLQBENIL™; DICHLONE™; DICHLORMID;DICHLOROPROPENE; DICHLORPROP; DICHLORVOS; DICLOFOP-ME; DICOFOL;DICROTOPHOS; DIELDRIN; DIENOCHLOR; DIFLUBENZURON; DIMETHIPIN;DIMETHIRIMOL; DIMETHOATE; DIMETHYLARSINIC ACID; DINITRAMINE; DINOCAP;DINOSEB; DIOXACARB; DIPROPETRYN; DIQUAT DIBROMIDE; DISULFOTON; DIURON;DNOC; DODINE ACETATE SALT; DSMA; ENDOSULFAN; ENDOTHALL; ENDRIN; EPN;EPTC; ESFENVALERATE; ETHALFLURALIN; ETHEPHON; ETHOFUMESATE; ETHOPROP;ETHYLENE DIBROMIDE; ETRIDIAZOLE; FENAMINOSULF; FENAMIPHOS; FENARIMOL;FENBUTATIN OXIDE; FENFURAM; FENITROTHION; FENOPROP; FENOXAPROP-ET;FENOXYCARB; FENPROPATHRIN; FENSULFOTHION; FENTHION; FENURON;FENVALERATE; FERBAM; FLUAZIFOP-BUTYL; FLUAZIFOP-P-BUTYL; FLUCHLORALIN;FLUCYTHRINATE; FLUMETRALIN; FLUMETSULAM; FLUOMETURON; FLUPYRSULFURONMETHYL; FLURIDONE; FLUSILAZOLE; FLUSILAZOLEH™; FLUSILAZOLE; FOMESAFEN;FONOFOS; FORMETANATE HCl; FOSAMINE AMMONIUM; FOSAMINE AMMONIUM; FOSETYLALUMINUM; GLUFOSINATE-AMMONIUM; GLYPHOSATE; HALOXYFOP-METHYL;HEPTACHLOR; HEXACHLOROBENZENE; HEXAZINONE; HEXAZINONEhtm; HEXAZINONEtxt;HYDRAMETHYLNON; IMAZALIL;IMAZAPYR ACID; IMAZAQUIN ACID; IMAZETHAPYR;IPRODIONE; ISAZOFOS; ISOFENPHOS; ISOPROPALIN; ISOXABEN; LACTOFEN;LENACIL; LENACILhtm; LENACILtxt; LINDANE; LINURON; MALATHION; MALEICHYDRAZIDE ACID; MANCOZEB; MANEB; MCPA; MCPB; MECOPROP; MEFLUIDIDE;MEPIQUAT CHLORIDE; METALAXYL; METALDEHYDE; METHAMIDOPHOS; METHAM SODIUM;METHAZOLE; METHIOCARB; METHOMYL; METHOXYCHLOR™; Methyl Bromide; MethylIsothiocyanate; Methyl Parathion; METIRAM™; METOLACHLOR™; METRIBUZIN™;METSULFURON ME™; MEVINPHOS™; MEXACARBATE™; MIREX™; MOLINATE™;MONOCROTOPHOS™; MONOLINURON™; MONURON™; MSMA™; MYCLOBUTANIL™; NALED™;Naphthalene; Napropamide; Naptalam Sodium Salt; NEBURON™; NICOSULFURON™;NITRAPYRIN™; NITROFEN™; NORFLURAZON™; ORYZALIN™; OXADIAZON™; OXAMYL™;OXYCARBOXIN™; OXYDEMETON-ME; OXYFLUORFEN; PACLOBUTRAZOL™; PARAQUATDICHLORIDE™; PARATHION™; PEBULATE™; PENDIMETHALIN™; Pentachlorophenol;Perfluidone; Perimiphos-Ethyl; PERMETHRIN™; PHENMEDIPHAM™; PHENTHOATE™;PHORATE™; PHOSALONE™; PHOSMET™; PHOSPHAMIDON™; PICLORAM™; PIPERALIN™;PIRIMICARB™; PIRIMIPHOS-ETHYL; PRIMISULFURON-METHYL; PROCHLORAZ;PROCYMIDONE; PRODIAMINE; PROFENOFOS; PROFLURALIN; PROMECARB™; PROMETON;PROMETRYN; PROPACHLOR; PROPAMOCARB HCL; PROPANIL; PROPARGITE™;PROPAZINE™; PROPHAM; PROPICONAZOLE; PROPOXUR; PROPYZAMIDE™; PYRETHRINS™;PYRITHIOBAC SODIUM; QUINOMETHIONATE™; QUINTOZENE; QUIZALOFOP-ET;RESMETHRIN; RIMSULFURON; ROTENONE™; SECBUMETON; SETHOXYDIM; SIDURON™;SIMAZINE™; SIMETRYN™; SODIUM CHLORATE; SULFOMETURON-ME; SULPROFOS;TAU-FLUVALINATE™; TCA-SODIUM; TEBUTHIURON; TEMEPHOS; TERBACIL; TERBUFOS;TERBUTRYN; TETRACHLORVINPHOS™; THIABENDAZOLE™; THIDIAZURON™;THIOBENCARB™; THIODICARB™; THIOPHANATE-ME™; THIRAM™; TOLCLOFOS-METHYL™;TOXAPHENE™; TRALOMETHRIN™; TRIADIMEFON™; TRIADIMENOL; TRIALLATE™;TRIASULFURON™; TRIBUFOS™; TRICHLORFON™; TRICHLORONAT™; TRICLOPYR™;TRICYCLAZOLE™; TRIDIPHANE™; TRIFLUMIZOLE™; TRIFLURALIN™; TRIFLUSULFURONMETHYL™; TRIFORINE™; TRIMETHACARB™; VINCLOZOLINT™; ZINEB™ and ZIRAM™.

Plant protection agents within the concept of the present invention areunderstood to include insecticides, acaricides, nematicides, repellants,fungicides, herbicides, rodenticides, and mulluscicides, as well asgrowth promoters and inhibitors and synergists. The chemical origin ofthese active substances is not critical. They may originate from themost varied classes of chemical compounds. The only requirement is thatthey must be stable under the manufacturing conditions for thecarrier/active substance combinations. Thus, compounds from, forexample, the chemical classes of the chlorocarbons (lindane and others),organophosphorus acid esters (parathion and others), carbamates(carbofuran and others), cyclodiene derivatives (endosulfan and others),pyrethroides, pyrethrins (cypermethrin and others), xanthogenates(dixanthogen and others), triazole derivatives (azocyclotin and others),organic sulfides (chlorfen sulfide and others), metal-organic compounds(cyhexatin and others), thiadiazine derivates (dazomet and others),phthalates (dimethylphthalate and others), morpholine derivatives(aldimorph and others), triazine derivatives (desmetryn and others),anilides (benodanil and others) imidazoles (benomyl and others),phthalimide derivatives (captan and others), sulfamides (dichlofluanidand others), pyrimidine derivatives (dimethirimol and others),thiadiazols (etridiazol and others), polymeric dithiocarbamates (maneband others), monomeric dithiocarbamates (sulfallate and others),oxazolidine derivatives (vinchlozolin and others), urea derivatives(monolinuron and others), benzoic acid derivatives (chlorothiamid,dichlobenil and others), phenoxyalkane acid derivatives (2,4-D andothers), aryl alkane acid derivatives (Fenac (for 2,3,6-trichlorophenylacetic acid) and others), aniline derivatives (fluchloralin and others),uracil derivatives (lenacil and others), pyridazone derivatives(chloridazon and pyrazon and others), thiourea derivatives (ANTU andothers), coumarin derivatives (coumafuryl and others), aryl alkanolderivatives (ancymidol and others), indolyl derivatives (indolylaceticacid and others), dialkane acid derivatives (maleic acid hydrazide andothers), chloralkane ether derivatives (octachlorodipropyl ether andothers), and sulfoxide derivatives (sulfoxides and others) can be usedin accordance with the present invention.

The term “foodstuff” encompasses all food items including, but notlimited to, baked goods, including bread, bread dough, cakes, biscuits,pies, rolls and the like; breakfast cereals; candy including chewing gumand chocolate; gelatin desserts; diary products including ice cream,cheese, yogurt, and milk; vegetable oil, beverages including fruitdrinks, tea, coffee, beer, wine and soft drinks; shortening includingbutter, vegetable oil, and margarine; cured meats; non-dairy whiteners;potato chips; whipping agent; artificial whipped cream, processed eggwhites; jelly; infant formula; salad dressing including mayonnaise andsandwich spreads.

Suitable adjuvants, diluents and carriers that are useful in preparingthe herbicidal, pesticidal and pharmaceutical mixtures of the inventionare well known to those skilled in the art.

Liquid carriers that can be employed include water, toluene, xylene,petroleum naphtha, crop oil, acetone, methyl ethyl ketone,cyclohexanone, trichloroethylene, perchloroethylene, ethyl acetate, amylacetate, butyl acetate, propylene glycol monomethyl ether and diethyleneglycol monomethyl ether, methanol, ethanol, isopropanol, amyl alcohol,ethylene glycol, propylene glycol, glycerine, N-methyl-2-pyrrolidinone,and the like. Water is generally the carrier of choice for the dilutionof concentrates.

Suitable solid carriers include talc, pyrophyllite clay, silica,attapulgus clay, kieselguhr, chalk, diatomaceous earth, lime, calciumcarbonate, bentonite clay, Fuller's earth, cotton seed hulls, wheatflour, soybean flour, pumice, wood flour, walnut shell flour, lignin,and the like.

Other adjuvants commonly utilised in compositions includecompatibilising agents, antifoam agents, sequestering agents,neutralising agents and buffers, corrosion inhibitors, dyes, odorants,spreading agents, penetration aids, sticking agents, dispersing agents,thickening agents, freezing point depressants, antimicrobial agents, andthe like.

The concentration of the active agents will obviously depend upon theend use and mode of action of the active agent. For example, withrespect to herbicidal compositions of this invention is generally fromabout 0.001 to about 98 percent by weight. Concentrations from about0.01 to about 90 percent by weight are often employed. In compositionsdesigned to be employed as concentrates, the active agent is generallypresent in a concentration from about 5 to about 98 weight percent,preferably about 10 to about 90 weight percent. Such compositions aretypically diluted with an inert carrier, such as water, beforeapplication.

Pesticidal active agent may be used alone; however, usually they areformulated into conventional forms such as dust, granule, microgranule,wettable powder, flowable powder, emulsion, microcapsule, oil, aerosol,etc., using techniques well known in the art. To improve or stabilisethe effects of the pesticide, the pesticide is blended with suitableadjuvants and then used as such or after dilution if necessary. Examplesof adjuvants include carriers, diluents, spreaders, emulsifying agents,wetting agents, dispersion agents, or fixing agents.

The amount of pharmaceutical active agent that may be combined with thecarrier materials to produce a single dosage form will vary dependingupon the host treated and the particular mode of administration. Forexample, a formulation intended for the oral administration of humansmay vary from about 5 to about 95% of the total composition. Dosage unitforms will generally contain between from about 1 mg to about 500 mg ofactive agent.

Having identified a substance for use in the present invention it isactivated as defined above. Preferably the substance or a component ofthe substance is vortexed for a period between 45 and 90 minutes asdescribed below and then agitated for 45 and 90 minutes as describedbelow to produce a fundamental quantum harmonic of between 20 to 50 Hz.

The vortexing and agitation may be by any means capable of forming thedesired harmonic as described below. Suitable means include using staticmixers (Maa, et al., J. Microencapsulation 13(4): 419-33 (1996)), aswell as dynamic mixing means such as agitators, homogenizers,sonicators, and other process equipment known in the art.

In one embodiment, the agitation is performed by blending the drysubstance or active agents together as described above with one or moreacceptable diluents, carriers or excipients then vortexing and agitatingthe substance or active agents through a length of pipe or tubing atconditions sufficient to create the desired harmonic, ie. enoughturbulence to induce harmonic formation.

Other static devices, such as restriction plates (flow constrictors) andfilters, also can be used to create the required harmonic. In apreferred embodiment, non-static mixers are used as the agitation means.As used herein, the term “non-static mixer” refers to a device havingelements that freely move within a flowing stream of the fluids to beagitated. Examples of non-static mixers include non-motorised turbinesand certain flow indicators, such as a ball indicator. Another exampleis a flow though mixer head available on a Silverson homogeniser.Non-static mixers advantageously provide more efficient agitation thanthat induced by turbulent flow alone, and can be less expensive thanmost dynamic and static mixers. These types of static and non-staticmixing means can be used to enhance or replace conventional agitationtechniques, such as agitators and static mixers, which may beparticularly useful when the process for making the nutrient formulationor composition of the invention is operated continuously at certainproduction rates. Mixing in a classic static mixer relies on a number offactors, including the rate of fluid flow. Pumps or pressure controlsthe fluid flow rate and can vary with pump oscillations or changingpressure. The use of a non-static mixer in a continuous process canovercome these oscillations by providing additional steady mixing,resulting in a more consistent emulsion. One of skill in the art canreadily optimise these mixing means to achieve the most efficientproduction of the desired harmonic.

Without wishing to be bound by any theory or hypothesis the applicantbelieves that by vortexing and agitating the substance or active agentas described herein a vortex in the substance or active agent of theinvention produces small amounts of rotons depending on speed and energyof the vortex. Rotons are second generation tachyons formed inoscillating vortex (See, for example, Shatskiy, A A, J. High EnergyPhys.: 11 (2001), pp. 064; Pismen, L. Phys. Rev. 2002, pp. 8). Thisoscillation is fundamental in producing the harmonics which are thebasis of the present invention.

In one particularly preferred embodiment the vortex is between 100 mmand 250 mm Radius and has a velocity to impart of between 50 to 100joules per second.

Calculation of the conditions to produce the specific harmonic is asfollows:˜K ^(d) +G _(t) ^(np)+Σ^(Eg) M=0where K^(d)=Thermal Density of Fluid

-   -   G_(t) ^(np) ((T+F+R){circumflex over ( )}-Pi    -   T=TEMPERATURE    -   Σ^(g)=HARMONIC MEAN OF FLUID    -   F=DESIRED HARMONIC FLUID    -   M=Mass of Fluid    -   R=Energy imparted to fluid

The harmonic may be measured by a protek multifunction counter 9100 orsimilar frequency meter. This is done by immersing a probe into theliquid formulation after agitation has occurred. The reading is thentaken of the fundamental harmonic of the agitated liquid.

In a preferred method the substance or active agent described above isvortexed at a low velocity to form a vortex in one direction of between30-120 rpm at which point the direction of vortex is reversed until thevortex reaches a velocity of between 30-120 rpm at which point thedirection of the vortex is reversed again and so repeated until a periodof 45 minutes to 90 minutes is reached.

While it is possible to use any vortex machine to produce theappropriate vortex it is preferable that the system uses the kineticenergy of isotropic fluids of a range between 40,000 and 80,000 kJ.

Once the appropriate vortex has been formed in the substance or activeagent it is then agitated at a rate of between 50,000-65,000 Kj/mole atan angle of 10-90 degrees at a frequency between 0.1-100 cycles persecond. During this step the solution is energised. This stage lastsbetween 45 to 90 minutes.

The substance or active agent may then succussed in the agitator at arate of 50000-65000 kj/mole at a angle 10-90 Degrees at a frequencybetween 0.1-100 cycles per second. During this step the solution isenergized. This stage lasts between 40 to 80 minutes. This solution iseither further diluted as in step 1 and returned to step 2 or packaged.

The final agitated substance or active agent can be administered to asubject either as solution, as an ointment or paste, as tablets, or inthe form of pellets or globules of a carrier, such as lactose.Alternatively, the substance can be manufactured into foodstuff,pharmacuetical preparations or other such material. It is also possibleto triturate the substance or active agent with a solid carrier. Tabletsor capsules may be of suitable size which are convenient for swallowing,for example about 0.2 g to about 1 g. The final substance may also be aliquid or a powder and may be added to other substances which may not beproduced by this process to make a final medicine or substance.

The substance or active agent can then either containerised orpotentised further as follows:

1 ml or 1 g of substance or active agent is mixed with 9 ml of diluentto produce 10 ml of 1× attenuation. This is then vortexed and rotatedthen agitated as described below where it is succussed. A furtherdilution of the processed substance or active agent can then be made asnecessary by taking 1 ml of 1× attenuation which is succussed with 9 mlsof diluent to produce 10 ml of 2× attenuation and so on. This may berepeated until the desired potency is achieved.

In one embodiment rather than blending the substance or active agentthen vortexing and agitating the entire substance, formulation orcomposition as described above it is possible to merely vortex one ormore of the agents separately then blend these agents together. Forexample, 1 gram of substance eg medicament, trace element, mineral,plant or animal material may be added to a volume of liquid of 15,000 to20,000 L and then vortexed and succussed resulting in a biomorphogenicmedicine.

The term “biomorphogenic” as used herein refers to the enhancement ofthe electrical potential of a substance by the creation of fundamentalharmonic profiles as described throughout the specification.

With respect to pharmaceutical substances or active agents of thepresent invention these may be administered orally, topically,parenterally, or by inhalation spray in dosage unit formulationscontaining non-toxic pharmaceutically acceptable carriers, adjuvants andvehicles. The term parenteral as used herein includes subcutaneousinjections, intravenous, or intramuscular.

A pharmaceutical substance or active agent of the invention may be in aform suitable for oral use, for example, as tablets, troches, lozenges,aqueous or oily suspensions, dispersible powders or granules, emulsions,hard or soft capsules, or syrups or elixirs. Compositions intended fororal use may be prepared according to any method known to the art forthe manufacture of pharmaceutical compositions and such compositions maycontain one or more agents selected from sweetening agents, flavouringagents, colouring agents and preserving agents in order to providepharmaceutically elegant and palatable preparations. Tablets contain theactive agent in admixture with non-toxic pharmaceutically acceptableexcipients which are suitable for the manufacture of tablets. Theseexcipients may be for example, inert diluents, such as calciumcarbonate, sodium carbonate, lactose, calcium phosphate or sodiumphosphate; granulating and disintegrating agents, for example cornstarch, or alginic acid; binding agents, for example starch, gelatin oracacia, and lubricating agents, for example magnesium stearate, stearicacid or talc. The tablets may be uncoated or they may be coated by knowntechniques to delay disintegration and absorption in the gastointestinaltract and thereby provide a sustained action over a longer period. Forexample, a time delay material such as glyceryl monostearate or glyceryldistearate may be employed. They may also be coated by the techniquesdescribed in the U.S. Pat. No. 4,256,108, U.S. Pat. No. 4,166,452 andU.S. Pat. No. 4,265,874, to form osmotic therapeutic tablets forcontrolled release.

Formulations for oral use may also be presented as hard gelatin capsuleswhere in the active agent is agitate with an inert solid diluent, forexample calcium carbonate, calcium phosphate or kaolin, or as softgelatin capsules wherein the active agent is agitate with water or anoil medium, for example peanut oil, liquid paraffin or olive oil.Aqueous suspensions contain the active materials in admixture withexcipients suitable for the manufacture of aqueous suspensions. Suchexcipients are suspending agents, for example sodiumcarboxymethylcellulose, methylcellulose, hydroxy-propylmethylcellulose,sodium alginate polyvinyl-pyrrolidone, gum tragacanth and gum acacia;dispersing or wetting agents may be a naturally occurring phosphatide,for example lecithin, or condensation products of an alkylene oxide withfatty acids, for example polyoxyethylene stearate, or condensationproducts of ethylene oxide with long chain aliphatic alcohols, forexample heptadecaethyleneoxycetanol, or condensation products ofethylene oxide with partial esters derived from fatty acids and ahexitol such a polyoxyethylene with partial esters derived from fattyacids and hexitol anhydrides, for example polyoxyethylene sorbitanmonooleate. The aqueous suspensions may also contain one or morepreservatives, for example ethyl, or n-propyl, p-hydroxybenzoate, one ormore colouring agents, one or more flavouring agents, and one or moresweetening agents, such as sucrose or saccharin.

Oily suspensions may be formulated by suspending the active agent in avegetable oil, for example arachis oil, olive oil, sesame oil or coconutoil, or in a mineral oil such as liquid paraffin. The oily suspensionsmay contain a thickening agent, for example beeswax, hard paraffin orcetyl alcohol. Sweetening agents such as those set forth above, andflavouring agents may be added to provide a palatable oral preparation.These compositions may be preserved by the addition of an anti-oxidantsuch as ascorbic acid.

Dispersible powders and granules suitable for preparation of an aqueoussuspension by the addition of water provide the active agent inadmixture with a dispersing or wetting agent, suspending agent and oneor more preservatives. Suitable dispersing or wetting agents andsuspending agents are exemplified, for example sweetening, flavouringand colouring agents may also be present.

The substance or active agent of the invention may also be in the formof oil-in-water emulsions. The oily phase may be a vegetable oil, forexample olive oil or arachis oil, or a mineral oil, for example liquidparaffin or mixtures of these. Suitable emulsifying agents may benaturally occurring gums, for example gum acacia or gum tragacanth,naturally occurring phosphatides, for example soya bean, lecithin, andesters or partial esters derived from fatty acids and hexitolanhydrides, for example sorbitan monooleate and condensation products ofthe said partial esters with ethylene oxide, for example polyoxyethylenesorbitan monooleate. The emulsions may also contain sweetening andflavouring agents.

Syrups and elixirs may be formulated with sweetening agents, for exampleglycerol, propylene glycol, sorbitol or sucrose or lactose. Suchformulations may also contain a demulcent, a preservative and flavouringand colouring agents. The pharmaceutical compositions may be in the formof a sterile injectable aqueous or oleagenous suspension. Thissuspension may be formulated according to the known art using thosesuitable dispersing or wetting agents and suspending agents which havebeen mentioned above. The sterile injectable preparation may also be ina sterile injectable solution or suspension in a non-toxic parenterallyacceptable diluent or solvent, for example as a solution in1,3-butanediol. Among the acceptable vehicles and solvents that may beemployed are water, Ringer's solution and isotonic sodium chloridesolution. In addition, sterile, fixed oils are conventionally employedas a solvent or suspending medium. For this purpose any bland fixed oilmay be employed including synthetic mono- or diglycerides. In addition,fatty acids such as oleic acid find use in the preparation ofinjectables.

Aerosols of liquid particles comprising the pharmaceutical substance oractive agent of the invention may be produced by any suitable means,such as with a nebuliser. See, eg., U.S. Pat. No. 4,501,729. Nebulisersare commercially available devices which transform solutions orsuspensions of the active agent into a therapeutic aerosol mist eitherby means of acceleration of a compressed gas, typically air or oxygen,through a narrow venturi orifice or by means of ultrasonic agitation.Suitable formulations for use in nebulisers consist of the active agentin a liquid carrier, the active agent comprising up to 40% w/w, butpreferably less than 20% w/w, of the formulation. The carrier istypically water or a dilute aqueous alcoholic solution, preferably madeisotonic with body fluids by the addition of, for example, sodiumchloride. Optional additives include preservatives if the formulation isnot prepared sterile, for example, methyl hydroxybenzoate, antioxidants,flavouring agents, volatile oils, buffering agents and surfactants.

The aerosols of solid particles comprising the active agent may likewisebe produced with any solid particulate medicament aerosol generator.Aerosol generators for administering solid particulate medicaments to asubject produce particles which are respirable, as explained above, andgenerate a volume of aerosol containing a predetermined metered dose ofa medicament at a rate suitable for human administration. Oneillustrative type of solid particulate aerosol generator is aninsufflator. Suitable formulations for administration by insufflationinclude finely comminuted powders which may be delivered by means of aninsufflator or taken into the nasal cavity in the manner of a snuff. Inthe insufflator, the powder, eg., a metered dose thereof effective tocarry out the treatments described herein, is contained in capsules orcartridges, typically made of gelatin or plastic, which are eitherpierced or opened in situ and the powder delivered by air drawn throughthe device upon inhalation or by means of a manually-operated pump. Thepowder employed in the insufflator consists either solely of the activeagent or of a powder blend comprising the active agent, a suitablepowder diluent, such as lactose, and an optional surfactant. The activeagent typically comprises from 0.1 to 100 w/w of the formulation.

A second type of illustrative aerosol generator comprises a metered doseinhaler. Metered dose inhalers are pressurised aerosol dispensers,typically containing a suspension or solution formulation of the activeagent in a liquefied propellant. During use these devices discharge theformulation through a valve adapted to deliver a metered volume,typically from 10 to 150 μl, to produce a fine particle spray containingthe active agent. Suitable propellants include certainchlorofluorocarbon compounds, for example, dichlorodifluoromethane,trichlorofluoromethane, dichlorotetrafluoroethane and mixtures thereof.The formulation may additionally contain one or more co-solvents, forexample, ethanol, surfactants, such as oleic acid or sorbitan trioleate,antioxidants and suitable flavouring agents.

The aerosol, whether formed from solid or liquid particles, may beproduced by the aerosol generator at a rate of from about 10 to 150litres per minute, more preferably from about 30 to 150 litres perminute, and most preferably about 60 litres per minute. Aerosolscontaining greater amounts of medicament may be administered morerapidly.

In one particular embodiment the substance or active agent of thepresent invention further comprises boron, which appears to helpmaintain calcium balance, keeping bones healthy and preventingosteoporosis. Preferably, adequate levels of boron (˜3-5 mg) in the dietto maintain healthy bones is required. Zinc may also be included as ithas been shown to reduce joint swelling and other symptoms in rheumatoidarthritis.

In a further preferred embodiment the substance or active agent of thepresent invention further comprises calcium. Calcium supplementationgiven at a 400 mg dose twice a day twice daily had been shown to avertbone loss and stabilized bone density in the spine, femoral neck, andradial shaft in women relatively soon after menopause.

In one embodiment the present invention provides a composition for usein the prevention and/or treatment of a medical disorder mediated inwhole or part by mineral deficiency and free radicals, comprising:

-   -   at least one vitamin;    -   at least one trace element; and    -   one homoeopathic and/or biomorphogenic ingredient.

Preferably, the vitamin is vitamin C, the trace elements comprise one ormore of magnesium, boron, zinc and sodium. Preferably, the calcium is inthe form of calcium citrate or calcium carbonate. The preferredcomposition also comprises ascorbic acid, sodium bicarbonate, magnesiumaspartate or magnesium orotate, seleno-methionine, boron and either zincoxide or zinc aspartate.

In one preferred embodiment the invention provides a pharmaceuticalsubstance or composition comprising: Ascorbic acid equivalent 30 to 250mg/g Calcium equivalent 80 to 100 mg/g Magnesium equivalent 2 to 2.5mg/g Zinc (picolinate) equivalent 3 to 20 mg/g Selenomethionineequivalent 0.002 to 0.0090 mg/g Na Bicarbonate equivalent 180 to 205mg/g Boron equivalent 0.001 to 0.005

Without wishing to be bound by any theory or hypothesis the applicantbelieves that the method of the present invention further preferablyresults in the scavenging of free radicals by the Phase I cytochromeP₄₅₀ system of the liver and the production of water soluble metabolitesof toxic xenobiotics via the Phase I cytochrome P₄₅₀ of the liver. ThePhase I cytochrome P₄₅₀ enzymes are believed to be benefited by thepresence of vitamin C, selenomethionine and zinc.

During Phase II cytochrome P₄₅₀ of the liver is further supported by thenutrient formulation by provision of mineral replacement, therebysupporting eliminatory organs—including the kidneys, and thecardiovascular system, including the heart and circulatory system andalso to correct mineral deficiencies.

In one especially preferred embodiment of the invention the method ofthe present invention may be used to treat and/or prevent any one or acombination of the following conditions arthritis, osteoporosis,tendonitis, fibromyalgia, trauma injury to soft tissues such asligaments and tendons or other to relieve symptoms caused by mineraldeficiency or assist regulation of immune function in disorders causedby free radical activity. This formulation shall be used to correctmetabolic pathways caused by enzyme deficiency due to vitamin andmineral deficiencies. The purpose of administering the dietarycomposition to patients is to stimulate certain enzymes of the bodywhich when sufficiently active are capable of clearing from the bodynumerous accumulated undesirable non-end product metabolites and toxins.Sources of such non-end product metabolites and toxins may beenvironmental, such as exposure to environmental xenobioticsubstances—ie. heavy metals, pesticides, herbicides, fungicides, alteredDNA fractions, poisons, certain drugs and pharmaceuticals, as well asexcessive levels of other non-end product metabolites which are formedin biochemical reactions in the body during states of alteredmetabolism. The human body's ability to enzymatically processundesirable metabolites and toxins is demonstrably enhanced as a resultof treatment in accordance with the present invention.

It will be understood, however, that the specific dose level for anyparticular subject will depend upon a variety of factors including theactivity of the specific compound employed, the age, body weight,general health, sex, diet time of administration, route ofadministration, rate of excretion, drug combination and the severity ofthe particular airway disease undergoing therapy.

In one embodiment, the substance comprises a liquid consisting of dryagents blended together. One particularly preferred nutrient formulationcomprises ascorbic acid (about equivalent 350 to 600 mg/g, calciumcitrate (about equivalent 60 to 80 mg/g, magnesium aspartate (aboutequivalent 0.9 to 1.6 mg/g, zinc picolinate (about equivalent 1 to 2mg/g, selenomethionine (about equivalent 0.005 to 0.01 mg/g, Nabicarbonate (about equivalent 130 to 140 mg/g boron from a homoeopathicor morphogenic source between 1× and 20×, and probiotic bacteria between1 to 10¹¹ cfu per gm blended together with between 400 ml to 1000 mlwater and 2% of a suitable “non toxic surfactant”. The term “non toxicsurfactant” may include lecithin or glycerol, potassium sorbate andethanol. The method of blending of the dry agents, water and surfactantis not essential and any standard techniques used in the art may beemployed.

The preferred formulation or composition may also include anutritionally acceptable soluble magnesium salt, for example in the formof magnesium aspartate or orotate. Other additives include solublecalcium salt, ascorbic acid derivative, for example calcium citrate,orotate or carbonate, sodium, potassium, magnesium aspartate or orotate,zinc ascorbate or picolinate or aspartate or oxide; ascorbic acid, or aszinc amino acid chelate, boron, selenomethionine as well aspharmaceutically acceptable buffering salt such as, for example, sodiumbicarbonate.

Co-pending application PCT/AU03/00103 (incorporated herein by reference)describes a specific airway disorder formulation. Consequently, thepresent application explicitly excludes such a formulation by proviso.

Throughout the specification, unless the context requires otherwise, theword “comprise” or variations such as “comprises” or “comprising”, willbe understood to imply the inclusion of a stated integer or group ofintegers but not the exclusion of any other integer or group ofintegers.

The invention will now be further described by way of reference only tothe following non-limiting examples. It should be understood, however,that the examples following are illustrative only, and should not betaken in any way as a restriction on the generality of the inventiondescribed above. In particular, while the invention is described indetail in relation to a specific asthma formulation, it will be clearlyunderstood that the findings herein are not limited to this formulation.For example, other formulations for other airway disease may be producedusing the techniques herein described as long as they comprise theharmonic disclosed.

EXAMPLE 1 Activation of Water

The frequency of tap water before energizing was 0. The Opticalabsorption of the water before excitation was 1.1 as measured byGallenkamp calorimeter in white light. The main vortex operated at 18rpm with a reversal at 6 seconds and with a gap of 4 second. The waterwas processed in the vortex processor for one hour. It reached initialprimary frequency of 9.75 Hz after about 15 minutes. After 60 minutesthe first process was stopped and water transferred to the second(succussion) stage. Its frequency before this stage was 249 Hz; duringthis stage the frequency was 9.8 Hz. The succussion rate was between 1and 8 succussions per second. This process lasted 60 minutes. The finalfrequency was 31.8 Hz. The Optical absorption of the water afterexcitation was 0.4 (measured by colourimeter).

EXAMPLE 2 Activation of Milk

The frequency before energizing was 6.6 Hz. The main vortex operated at18 rpm with a reversal at 5 seconds and with a gap of 5 seconds. Themilk was processed in the vortex processor for one hour. It reachedinitial primary frequency of 9.81 Hz after about 12 minutes. After 60minutes the first process was stopped and the milk transferred to thesecond (succussion) stage. Its frequency before this stage was 227 Hz.During this stage the frequency was 9.6 Hz. The succussion rate wasbetween 1 and 8 succussions per second. This process lasted 60 minutes.The Final frequency was 31.08 Hz. As shown in Table 1 milk showedpronounced biological activity after excitation by increasedlactobacillus growth during later culturing in a laboratory setting.TABLE 1 Bacterial Bacterial Percentage Growth Before Growth AfterIncrease after Cfu/ml Cfu/ml Excitation of milk Lactobacillus 140000000850000000 607.1428571 acidophilus Lactobacillus 300000000 860000000286.6666667 plantarum Lactobacillus 3200000 1900000000 59375 brevisLactobacillus 4200000 980000000 23333.33333 delbruccei Lactobacillus400000 5000000000 1250000 salivarus Bifido 400000 110000000 27500Bacterium

EXAMPLE 3 Asthma Formulation Preparation

The applicant produced an asthma medicament as follows: Ascorbic acidequivalent 250-350 mg/g Calcium citrate equivalent 55 to 62 mg/gMagnesium aspartate equivalent 2 to 2.5 mg/g Zinc oxide equivalent 9.64to 21 mg/g Selenomethionine equivalent 0.01 to 0.10 mg/g Na Bicarbonateequivalent 140 mg/g to 180 mg/g Boron equivalent 0.00000001 to 0.05 mg/gProbiotic Bacteria between 1 to 10¹¹ cfu per gm.

These ingredient were blended together. Daily dosages could range frombetween 0.125 mg for infants up to about 6 grams for adults. In order toproduce a liquid formulation the appropriate dosage amounts of theformulation was mixed with between 400 to 1000 ml of water and 2%surfactant was added.

The formulation was then vortexed for 45-90 minutes at 30-120 rpm asdescribed above to produce the fundamental quantum harmonic of between20 to 50 Hz as measured by protek multifunction counter 9100 frequencymeter.

Table 2 shows a series of frequency measurements taken by protekmultifunction counter 9100 frequency meter TABLE 2 EXAMPLES OFFREQUENCIES OF DIFFERENT FLUID MEDIUMS End End Initial Vortex VortexVortex Time Succussion Succussion Time Material Frequency FrequencyFrequency Speed Vortex Frequency Frequency Succussion Water 0 9.75 24918 60 9.8 31.8 60 Milk 6.6 9.81 227 18 60 9.6 31.01 60 Nutrient 5.99.819 239 18 60 9.85 31.65 55of liquids prior to agitation and after agitation.

The experimental data shown in Table 3 indicates that energy wasimparted into the liquid medium during the vortexing and agitatingprocess. This is further proven by the measurement of frequencies of theliquid medium before and after processing which show improvementsof >100%. All frequencies were measured by protek multifunction counter9100 frequency meter method.

Bioresonance testing was completed on the fluid mediums of H₂O, milk andliquid nutrient formulation. These were tested by the BioresonanceMethod of Schimmel (Schimmel, H 1986, Bioenergetic Regulatory TechniquesVEGA Gieshaber GmbH & Co Am Hohenstein 113 PO 1142D 7-622 ScitachGermany). Increases in resonance show improvements of between 20 and40%. The optical density was measured by Englehart colorimeter andshowed improvements of >75%.

The frequencies of the post agitation frequencies remained constant at arange of between 20 and 50 Hz and revealed that the fundamental harmonicof the agitated materials H₂O, milk and nutrient formulation to bemaintained and therefore a stable biomorphogenic end product attained.

Once produced the formulation was then ready to be administered topatients as a medicine in order to stimulate certain enzymes of the bodywhich when sufficiently active are capable of clearing from the bodynumerous accumulated undesirable non-end product metabolites and toxinsTABLE 3 EXAMPLES OF BIORESONANCE AND OPTICAL CHARACTERISTICS IncreasePre-Optical Post-Optical Bioresonance % Bioresonance % Bioresonance %Characterisitic Characterisitic 45 85 40 1.1 0.4 80 100 20 na na 80 10020 1.9 1.1

EXAMPLE 4 Asthma Medicament in Water

Between 30-75 g of powdered asthma medicine as described in example 3was added to a volume of water between 500 ml and 20,000 ml. Thefrequency before energizing was 5.9. The optical absorption of the waterbefore excitation was 1.9 as measured by Gallenkamp colorimeter in whitelight. The main vortex operated at 18 rpm with a reversal at 6 secondsand with a gap of 4 second. The solution was processed in the vortexpart for one hour. It reached initial primary frequency of 9.81 Hz afterapproximately 15 minutes. After 60 minutes the first process was stoppedand solution transferred to the second (succussion) Stage. Its frequencybefore this stage was 239 Hz. During this stage the frequency was 9.85Hz. The succussion rate was between 1 and 8 succussions per second. Thisprocess lasted 60 minutes. The Final frequency was 31.65 Hz, The Opticalabsorption of the solution after excitation was 1.1.

EXAMPLE 5 Dilution of Asthma Medicament in Water

10 mls of solution obtained from the end of processing in Example 4 wasmixed with 20 litre of water. The frequency before energizing was 8.2.The Optical absorption of the water before excitation was 1.9 asmeasured by Gallenkamp colorimeter in white light. The main vortexoperated at 18 rpm with a reversal at 6 seconds and with a gap of 4second. The solution was processed in the vortex part for one hour. Itreached initial primary frequency of 9.79 Hz after 15 minutes. After 60minutes the first process was stopped and solution containing themedicine transferred to the second (succussion) stage. Its frequencybefore this stage was 241 Hz. During this stage the frequency was 9.81Hz. The succussion rate was between 1 and 8 succussions per second. Thisprocess lasted 60 minutes. The Final frequency was 31.01 Hz. The Opticalabsorption of the solution after excitation was 1.1 as measured byGallenkamp colorimeter in white light.

EXAMPLE 6 Asthma Medicament in Water

10 mls of solution obtained from the end of processing Example 5 wasmixed with 20 litre of water. The frequency before energizing was 8.2.The Optical absorption of the water before excitation was 1.9 asmeasured by Gallenkamp calorimeter in white light. The main vortexoperated at 18 rpm with a reversal at 6 seconds and with a gap of 4second. The solution was processed in the vortex part for one hour. Itreached initial primary frequency of 9.81 Hz after 15 minutes. After 60minutes the first process was stopped and solution transferred to thesecond (succussion) stage. Its frequency before this stage was 239 Hz.During this stage the frequency was 9.8 Hz. The succussion rate wasbetween 1 and 8 succussions per second. This process lasted 60 minutes.The Final frequency was 31.65 Hz. The Optical absorption of the solutionafter excitation was 1.1.

EXAMPLE 7 Antioxidant Medicament in Water

An antioxidant medicament as shown in Table 4, was produced by themethod of Example 1. TABLE 4 Dosage of antioxidant subcutaneous and orintravenous or intramuscular medicine Minimum range Maximum range mg/mlmg/ml Ascorbic acid 0.1 2 Calcium 0.1 2 Magnesium 0.001 1 Zincpicolinate 0.001 2 seleno-methionine 0.00001 0.1 Na bicarbonate 0.1 2Boron 0.00001 2 Probiotics measured in cfu/ml Lactobacillius acidophilus1 × 10¹ 1 × 10¹¹ Lactobacillius brevis 1 × 10¹ 1 × 10¹¹ Lactobacilliuscasei 1 × 10¹ 1 × 10¹¹ Lactobacillius delbruceii 1 × 10¹ 1 × 10¹¹Lactobacillius rhamnosus 1 × 10¹ 1 × 10¹¹ Lactobacillius rhamnosus 1 ×10¹ 1 × 10¹¹ Lactobacillius plantarum 1 × 10¹ 1 × 10¹¹ Lactobacilliussalivarus 1 × 10¹ 1 × 10¹¹ BiffidoBacterium bifidum 1 × 10¹ 1 × 10¹¹

The frequency before energizing was 8.3. The Optical absorption of thewater before excitation was 1.9 as measured by Gallenkamp colorimeter inwhite light. The main vortex operated at 18.5 rpm with a reversal at 6seconds and with a gap of 4 second. The solution was processed in thevortex part for one hour. It reached initial primary frequency of 9.81Hz after about 15 minutes. After 60 minutes the first process wasstopped and solution transferred to the second (succussion) stage. Itsfrequency before this stage was 246 Hz During this stage the frequencywas 9.75 Hz. The succussion rate was between 1 and 8 succussions persecond. This process lasted 60 minutes. The Final frequency was 31.09Hz. The Optical absorption of the solution after excitation was 1.1 asmeasured by Gallenkamp calorimeter in white light.

EXAMPLE 8 Antioxidant Medicament—IV/SC Injection

Between 30-75 g of powdered antioxidant medicine as described in Example7 was added to a volume of physiological saline of between 500 ml and20,000 ml. The frequency before energizing was 4.67. The Opticalabsorption of the water before excitation was 1.9. The main vortexoperated at 18.5 rpm with a reversal at 6 seconds and with a gap of 4second. The solution was processed in the vortex part for one hour. Itreached initial primary frequency of 9.81 Hz after about 15 minutes.After 60 minutes the first process was stopped and solution transferredto the second (succussion) Stage. Its frequency before this stage was251 Hz. During this stage the frequency was 9.81 Hz The succussion ratewas between 1 and 8 succussions per second. This process lasted 60minutes. The Final frequency was 31.09 Hz. The Optical absorption of thesolution after excitation was 1.1 as measured by Gallenkamp colorimeterin white light.

EXAMPLE 9 Clinical Trial of Antioxidant Medicine on Guinea Pigs

A sample of the antioxidant medicament described in Example 8 was madeinto a subcutaneous/intravenous solution by sterilising it in a standardhospital autoclave. A measured volume of sterilised solution of between0.1 and 1 ml was then injected into a guinea pig. No adverse skineruption at the site of injection or adverse side effect was notedfollowing injections over several days.

Previous work by Linus Pauling institute has also demonstrated safety ofhigh dose ascorbic acid in guinea pigs. These studies were conducted toinvestigate whether ascorbic acid protected guinea pigs from aflatoxinB1 (AFB1) toxicity. Young guinea pigs, fed either 0 (AA) or 25 mg (25AA) or gavaged 300 mg ascorbic acid (300 AA) per day for 21 days, weregavaged with the LD50 dose of AFB1 on the 22nd day. Seven out of 10animals in the AA group died within 72 hr of AFB1 administration. Thelivers of the animals showed regional massive necrosis and multilobulardegeneration. There was no mortality in the 25 AA group. Their livers,however, showed changes similar to those seen in AA group. Serum alanineamino transferase (ALAT) and aspartate amino transferase (ASAT) levelswere elevated. There was neither mortality nor pathological changes inlivers in the 300 AA group. Their ALAT and ASAT levels were unaffected.In vitro production of AFM1 by liver microsomes tended to be higher thanthat in the other two groups. Three animals saved from the 300 AA groupand continued with their supplementation were administered a second,intraperitoneal (ip) LD50 dose of AFB1 1 month after the first AFB1dose. One animal died. Livers of the animals showed centrilobulardegeneration and moderate necrosis in scattered hepatocytes. Livermicrosomal cytochrome P450 and cytosolic glutathione S-transferase (GST)levels and AFM1 production were drastically reduced. ALAT and ASATactivities were raised. The results indicated that intake of 300 mg ofascorbic acid almost protected the animals from acute toxicity of AFB1when given by gavage, but not when administered as a second dose ip.

EXAMPLE 10 Clinical Trial of Antioxidant Medicament in a Herd of DairyGoats

A sample of the antioxidant medicament described in Example 8 was madeinto a subcutaneous/intravenous solution by sterilising it in standardhospital autoclave. A measured volume of sterilised solution of betweenand 1 ml and 2 mls was then injected subcutaneously into 100 goats. Noadverse skin eruption at the site of injection or adverse side effectwas noted in the goats following injections over several days and weeks.

Prior to the subcutaneous injections of the goats, milk obtained fromthe goats was cultured on agar plates. Upon microbial examination at ahospital laboratory, Lactococcus lactis and Enterococcus durans wereobserved. These organisms had grown to a count of over 1 millionorganisms per ml in the milk and were causing exotoxins and enterotoxinsto be released. This was resulting in gut stasis and death in 12 goats.Following 2 subcutaneous injection of the antioxidant medicament therewere no more reported deaths or signs of illness. Moreover, thebacterial count for Lactococcus lactis and Enterococcus durans haddropped from over 1×10⁶ to less than 3,400 for each species.

EXAMPLE 11 Asthma Medicament—IV/SC Injection

Between 30-75 g of powdered asthma medicament as described in Example 3was added to a volume of water between 500 ml and 20,000 ml. Thefrequency before energizing was 4.34. The optical absorption of thewater before excitation was 1.9 as measured by Gallenkamp calorimeter inwhite light. The main vortex operated at 18 rpm with a reversal at 6seconds and with a gap of 4 second. The solution was processed in thevortex part for one hour. It reached initial primary frequency of 9.75Hz after 15 minutes. After 60 minutes the first process was stopped andsolution transferred to the second (succussion) Stage. The frequencybefore this stage was 239 Hz. During this stage the frequency was 9.8Hz. The succussion rate was between 1 and 8 succussions per second. Thisprocess lasted 60 minutes. The Final frequency was 31.08 Hz. The Opticalabsorption of the solution after excitation was 1.1 as measured byGallenkamp calorimeter in white light.

EXAMPLE 12 Clinical Trial of Asthma Medicament in Guinea Pig

A sample of the asthma medicament described in Example 11 was made intoa subcutaneous/intravenous solution by sterilising it in standardhospital autoclave. A measured volume of sterilised solution of between0.1 and 1 ml was then injected into a guinea pig. No adverse skineruption at the site of injection or adverse side effect was notedfollowing injections over several days.

EXAMPLE 13 Clinical Trial of Asthma Medicament in Herd of Dairy Goats

A sample of the asthma medicament described in Example 11 was made intoa subcutaneous/intravenous solution by sterilising it in standardhospital autoclave. A measured volume of sterilised solution of betweenand 1 ml and 2 mls was then injected subcutaneously into 100 goats. Noadverse skin eruption at the site of injection or adverse side effectwas noted in the goats following injections over several days and weeks.

EXAMPLE 14 Activation of Ginseng

A preparation of the herb Ginseng was made by soaking some ginseng rootin vinegar overnight. This was then pureed the next day, filtered andthe resulting filtrate added to a volume of water between 500 ml and20,000 ml of water. The frequency before energizing was 3.65. The mainvortex operated at 18.5 rpm with a reversal at 6 seconds and with a gapof 4 second. The solution was processed in the vortex part for one hour.It reached initial primary frequency of 9.6 Hz after about 15 minutes.After 60 minutes the first process was stopped and solution transferredto the second (succussion) stage. Its frequency before this stage was255 Hz. During this stage the frequency was 9.8 Hz. The succussion ratewas between 1 and 8 succussions per second. This process lasted 60minutes. The Final frequency was 31.08 Hz.

EXAMPLE 14 Preparation of Snail Repellent

A snail repellent was made by taking a mature snail and soaking it invinegar overnight. The snail was then pureed the next day and added to avolume of water between 500 ml and 20,000 ml. The frequency beforeenergizing was 0.18. The optical absorption of the water beforeexcitation was 2 as measured by Gallenkamp colorimeter in white light.The main vortex operated at 18.5 rpm with a reversal at 6 seconds andwith a gap of 4 second. The solution was processed in the vortex partfor one hour. It reached initial primary frequency of 9.81 Hz afterapproximately 15 minutes. After 60 minutes the first process was stoppedand solution transferred to the second (succussion) stage. Its frequencybefore this stage was 255 Hz During this stage the frequency was 9.75Hz. The succussion rate was between 1 and 8 succussions per second. Thisprocess lasted 60 minutes. The Final frequency was 31.65 Hz. The Opticalabsorption of the solution after excitation was 1.2 as measured byGallenkamp colorimeter in white light.

When the repellent had completed the frequency process (Vortex andsuccussion) it was sprayed on a test snail. Before spraying the snailhad a frequency of 5.6, after 5 minutes this had dropped to 3.4. Within45 minutes this had dropped to 1.6 and within 1 hour the snail was dead.

This was similarly observed on 100 snails in a domestic garden. Thosesnails not directly sprayed left the vicinity of spraying within a 24hour period.

EXAMPLE 15 Preparation of Moth Repellent

A preparation of a moth was made by taking a mature moth and soaking itin vinegar overnight. The moth was then pureed the next day and added toa volume of water between 500 ml and 20,000 ml of water. The frequencybefore energizing was 0.36. The main vortex operated at 18.6 rpm with areversal at 6 seconds and with a gap of 4 second. The solution wasprocessed in the vortex part for one hour. It reached initial primaryfrequency of 9.81 Hz after approximately 15 minutes. After 60 minutesthe first process was stopped and solution transferred to the second(succussion) stage. Its frequency before this stage was 259 Hz. Duringthis stage the frequency was 9.75 Hz. The succussion rate was between 1and 8 succussions per second. This process lasted 60 minutes. The Finalfrequency was 31.05 Hz.

EXAMPLE 16 Preparation of Fly Repellent

A preparation of a fly repellent was made by taking a mature fly andsoaking it in vinegar overnight. The fly was then pureed the next dayand added to a volume of water between 500 ml and 20,000 ml of water thenext day The frequency before energizing was 0.36. The main vortexoperated at 18.6 rpm with a reversal at 6 seconds and with a gap of 4second. The solution was processed in the vortex part for one hour. Itreached initial primary frequency of 9.81 Hz after about 15 minutes.After 60 minutes the first process was stopped and solution transferredto the second (succussion) Stage. Its frequency before this stage was259 Hz During this stage the frequency was 9.75 Hz The succussion rateis 1 to 8 succussions per second. This process lasted 60 minutes. TheFinal frequency was 31.05 Hz.

EXAMPLE 17 Preparation of Herbicide

A preparation of the “weed” oxalis was made by soaking some oxalis invinegar overnight. This was then pureed the next day, filtered and theresulting filtrate added to a volume of water between 500 ml and 20,000ml of water. The frequency before energizing was 1.4. The main vortexoperated at 18.6 rpm with a reversal at 6 seconds and with a gap of 4second. The solution was processed in the vortex part for one hour. Itreached initial primary frequency of 9.67 Hz after approximately 15minutes. After 60 minutes the first process was stopped and solutiontransferred to the second (succussion) stage. Its frequency before thisstage was 259 Hz. During this stage the frequency was 9.68 Hz. Thesuccussion rate was 1 to 8 succussions per second. This process lasted60 minutes. The Final frequency was 31.07 Hz.

EXAMPLE 18 Preparation of Organic Biodynamic Fertiliser

A sample of between 1 and 10 g of Biodynamic Preparation “500”™ wasplaced with a volume of water between 500 ml and 20,000 mls. Thefrequency before energizing was 5.8. The main vortex operated at 18.6rpm with a reversal at 6 seconds and with a gap, of 4 second. Thesolution was processed in the vortex part for one hour. It reachedinitial primary frequency of 9.8 Hz after about 15 minutes. After 60minutes the first process was stopped and water transferred to thesecond (succussion) stage. Its frequency before this stage was 261 Hz.During this stage the frequency was 9.68 Hz. The succussion rate was 1-8succussions per second. This process lasted 60 minutes. The Finalfrequency was 31.08 Hz.

EXAMPLE 19 Preparation of Liquid Nutrient Formulation

A liquid nutrient formulation was prepared comprising at between 200mg/g to 600 mg/g equivalent ascorbic acid; between 50 mg/g to 200 mg/gequivalent calcium citrate carbonate or orotate; between 1.5 mg/g to 20mg/g equivalent magnesium aspartate or magnesium sulphate or orotate;between 5 mg/g to 30 mg/g equivalent zinc oxide or equivalent zincpicolinate 0.1 mg/g to 5 mg/g; between 0.001 mg/g to 0.1 mg/g equivalentseleno-methionine; equivalent sodium bicarbonate 100 to 300 mg/gequivalent Na content and equivalent boron 0.00000001 mg/g to 2 mg/g.Between 1 cfu and 1×10¹¹ cfu per ml of probiotic bacteria was alsoadded. The probiotic bacteria were Lactobacillus acidophilus;Lactobacillus brevis; Lactobacillus casei; Lactobacillus delbruceii;Lactobacillus rhamnosus; Lactobacillus plantarum; Lactobacillussalivarus and BifidoBacterium bifidum.

In this form the preferred dosage includes a range of between 1× and1:1000 ratio with dilution of liquid (water or ethanol). The latterbeing 1:1M homoeopathic following equivalent dilution of powderpreparation—i.e. between 1:1 ration and preparation in which dilutionsare succussed as followed: 2 ml of tincture is succussed with 8 ml ofdiluent to produce 10 ml of 2× attenuation, 1 ml of 2× attenuation isthen succussed with 9 mls of diluent to produce 10 ml of 3× attenuationand so on. This is repeated until the desired potency is acquired.Suspension in alcohol is the specified menstruum for the final decimalor centesimal attenuation when intended for medical purposes. The amountof alcohol will vary from between 2-60% depending on the desiredpotency.

EXAMPLE 20 Preparation of Powdered Nutrient Formulation

A powdered formulation of the liquid nutrient formulation may beobtained either by blending the ingredients shown without water orlyophilising the liquid nutrient formulation after vortexing andsuccussion process.

The liquid or powdered nutrient formulation is designed to utiliseingredients which have low allergenic potential or no known tendency tocause allergies, have no artificial chemical residues present onanalysis conducted by presently scientifically accepted analyticalmethods, and contain nutrients and substances which cause increasedactivity of hepatic enzymes. When used as a total dietary replacementduring times of acute dehydration or diarrhoea, the nutrient formulationof the present invention is also designed to provide substantially allnutrients and vitamins required by the human body, and thus to provide asubstantially balanced diet.

EXAMPLE 21 Preparation of Probiotic Bacteria

The protocol for culturing probiotic bacteria is as follows:

Milk either pasteurised or unpasteurised is used as a medium forculturing the bacteria. The milk is processed in the vortex and thensuccussed prior to culture being added If pasteurised milk is used thetemperature must reach 72° C. for 15 seconds or more. A starter cultureof probiotic bacteria comprising the 8 varieties shown above are addedseparately. The milk is then incubated between 37° C. and 43° C. toallow growth of more bacteria. During incubation the pH should reach 4.5to allow the correct balance of beneficial bacteria to be absorbed bythe human host consuming the product. The cultures are then dried andcapsulated either individually or with additional ingredients. Thepowder is either capsulated or containerised under an inert gas inairtight containers.

The purpose of administering the dietary composition to patients is tostimulate certain enzymes of the body which when sufficiently active arecapable of clearing from the body numerous accumulated undesirablenon-end product metabolites and toxins. Sources of such non-end productmetabolites and toxins may be environmental, such as exposure toenvironmental xenobiotic substances—i.e. heavy metals, pesticides,herbicides, fungicides, altered DNA fractions, poisons, certain drugsand pharmaceuticals, as well as excessive levels of other non-endproduct metabolites which are formed in biochemical reactions in thebody during states of altered metabolism—the formulation is able todetoxify infectious organisms such as bacteria, viruses and fungi. Allof these may cause oxidative damage to cells.

EXAMPLE 22 Asthma Clinical Trial

109 candidates with asthma were selected at random and trialed on thenutrient composition described in Example 1 for a period of 1 month.Over a 4 week period Symptom charts noting frequency of cough, wheezeand shortness of breath were kept by the candidates. Weeklyquestionnaires denoting drug dosage and frequency of symptoms were alsoreturned to the sponsor. Comparisons of symptoms and drug dosage weremade comparing pre and post supplementation with the nutrientcomposition.

Some of the symptom severities were recorded using fractional values(eg. 0.25) instead of the categories of Nil (0), Mild (1), Moderate (2)and Severe (3). To make use of these entries, the severity values wererounded to the nearest integer using the following scheme:

-   -   If 0≦severity<0.5 then severity=0.    -   If 0.5≦severity<1.5 then severity=1.    -   If 1.5≦severity<2.5 then severity=2.    -   If 2.5≦severity<3.0 then severity=3.

The frequency and percentage distributions of the reportedbronchodilator use at enrolment and after four weeks of treatment wereexamined to get an indication of whether a change had occurred.

Cross tabulations of the symptom severities at enrolment and after thefour weeks of treatment were performed to describe how the severitieshad changed and to what degree over this period.

Differences in bronchodilator use before and after the treatment periodwe compared using paired t tests. The symptom severity values areordinal variables so the Wilcoxon rank sum test was used to determinewhether the baseline and week four symptom severity distributionsdiffered primarily in location. That is whether one of the distributionshas been shifted left or right of the other.

One-sided tests of significance were used since it was expected that thetreatment would improve the severity of the symptoms and reduce theamount of bronchodilators used by the subjects. All tests of statisticalsignificance were made at the 5% level.

Symptom Severity Cross Tabulations

Coughing

From Table 5 67.9% (74 of 109) subjects had some reduction in theseverity of their coughing after four weeks of the treatment, 27.5% (30of 109) remained the same and 4.6% (5 of 109) got worse. This was likelydue to an inadequate daily dose and also the winter influenza outbreak.

Among those who initially had severe coughing after the treatment, 37.1%(13 of 35) did not report any coughing, 37.1% (13 of 35) reported mildcoughing, 14.3% (5 of 35) reported coughing of moderate severity and11.4% (4 of 35) reported no improvement (Table 5). TABLE 5 CROSSTABULATION OF COUGH SEVERITY AT ENROLMENT BY COUGH SEVERITY AFTER FOURWEEKS OF TREATMENT Cough Severity After Treatment Cough severity NilMild Moderate Severe Total at enrolment N % N % N % N % N Nil 13 100 0 00 0. 0 0.00 13 Mild 13 50 9 34.6 2 7.7 2 7.69 26 Moderate 16 45.7 1440.0 4 11.4 1 2.86 35 Severe 13 37.1 13 37.1 5 14.3 4 11.43 35 Total 5536 11 7 109Shortness of Breath

A similar pattern was found for shortness of breath and wheezing.

For shortness of breath, 78.9% (86 of 109) reported a reduction inseverity, 18.3% (20 of 109) reported no change and 2.8% (3 of 109)reported getting worse (Table 6).

For those who initially reported having a severe shortness of breath,28.8% (11 of 41) reported no shortness of breath after four weeks oftreatment, 39.0% (16 of 41) had moved to the mild category, 19.5% (8 of41) were in the moderate category and 14.6% (6 of 41) reported no change(Table 6). TABLE 6 CROSS TABULATION OF SHORTNESS OF BREATH SEVERITY ATENROLMENT BY SHORTNESS OF BREATH SEVERITY AFTER FOUR WEEKS OF TREATMENTShortness of breath Shortness of breath severity after treatmentseverity at Nil Mild Moderate Severe Total enrolment N % N % N % N % NNil 3 100.00 0 0.00 0 0.00 0 0.00 3 Mild 11 57.89 5 26.32 2 10.53 1 5.2619 Moderate 21 45.65 18 39.13 6 13.04 1 2.17 46 Severe 11 26.83 16 39.028 19.51 6 14.63 41 Total 46 39 16 8 109Wheezing

For the wheezing symptom, 68.8% (75 of 109) showed some improvement insymptoms, 28.4% (31 of 109) did not change and 2.8% (3 of 109) wereworse off (Table 7).

For those initially in the severe-wheezing category, 37.5% (12 of 32)reported no wheezing after treatment, 34.4% (11 of 32) were in the mildgroup, 12.5% (4 of 32) had moved to the moderate group and 15.6% (5 of32) reported no improvement. (Table 7). TABLE 7 CROSS TABULATION OFWHEEZE SEVERITY AT ENROLMENT BY WHEEZE SEVERITY AFTER FOUR WEEKS OFTREATMENT Wheeze Wheeze severity after treatment severity at Nil MildModerate Severe Total enrolment N % N % N % N % N Nil 12 100 0 0 0 0 0 012 Mild 13 50 12 46.2 1 3.9 0 0 26 Moderate 18 46.2 17 43.6 2 5.1 2 5.139 Severe 12 37.5 11 34.4 4 12.5 5 15.6 32 Total 55 40 7 7 109Bronchodilator t Test

From the paired t tests on the amount of bronchodilators doses used, asignificant decrease in the amount of Ventolin taken via puffer(p-value=0.0007) and nebuliser (p-value=0.0176), as well as Seretide(p-value=0.0084) and Flixotide (p-value=0.0400) after the four weektreatment period (Table 8).

An examination of the usage data for the other bronchodilators in thedata set showed that only a small proportion of the subjects (at most15%) used these other products/substances. With such small numbersmeaningful analyses could not be performed on these other data. TABLE 8PAIRED T TEST RESULTS FOR STATISTICALLY SIGNIFICANT CHANGES INBRONCHODILATOR USE BETWEEN ENROLMENT AND AFTER TREATMENT BronchodilatorDF t Value Pr > |t| Ventolin 107 −3.49 0.0007 Ventolin Nebuliser 108−2.41 0.0176 Seretide 108 −2.69 0.0084 Flixotide 108 −2.08 0.0400*Please note, these values are statistically significant at the 5%level.

Ventolin puffer use fell from a mean of 3.8 doses at enrolment to 1.7after four weeks of treatment. The use of Seretide, Flixotide andVentolin via nebuliser also fell after four weeks of treatment bysmaller amounts in absolute terms, however, the proportional change wassimilar (Table 9). TABLE 9 MEAN AND MEDIAN NUMBER OF DOES OFBRONCHODILATOR USE BETWEEN ENROLMENT AND AFTER TREATMENT MeanBronchodilator (enrolment) Mean (week 4) Ventolin 3.8 1.7 VentolinNebuliser 0.7 0.2 Seretide 1.0 0.6 Flixotide 0.5 0.3Symptom Severity Non-Parametric TestsCough

The Wilcoxon tests suggest that one of the distributions has asignificantly higher cough severity scores than the other (Norm approxZ=7.5365, p-value<0.0001) (Table 10). Using the information from Table 5it can be seen that the severities at the time of enrolment were moresevere than the values after the four weeks of treatment. TABLE 10WILCOXON TWO SAMPLE TEST RESULTS FOR CHANGES IN COUGH SEVERITY WilcoxonTwo-Sample Test Statistic 15320.5 Normal Approximation Z 7.5365One-Sided Pr > Z <.0001 Two-Sided Pr > |Z| <.0001 t ApproximationOne-Sided Pr > Z <.0001 Two-Sided Pr > |Z| <.0001Z includes a continuity correction of 0.5.Shortness of Breath

Similarly the Wilcoxon test for shortness of breath indicated that therewas a statistically significant difference in the distributions ofseverities at enrolment and after four weeks for this symptom (Normapprox Z=8.7827, p-value<0.0001) (Table 11). From Table 6 it can be seenthat the severities reported at enrolment were more severe than afterthe treatment period. TABLE 11 WILCOXON TWO SAMPLE TEST RESULTS FORCHANGES IN SHORTNESS OF BREATH SEVERITY Wilcoxon Two-Sample TestStatistic 15891.5 Normal Approximation Z 8.7827 One-Sided Pr > Z <.0001Two-Sided Pr > |Z| <.0001 t Approximation One-Sided Pr > Z <.0001Two-Sided Pr > |Z| <.0001Z includes a continuity correction of 0.5.Wheeze

There were statistically significant differences in the distribution ofseverities for wheezing between the initial severities and thoserecorded after four weeks. With the information from Table 7 it can beseen in Table 12 that there was a statistically significant improvementin the severities of wheezing after four weeks of treatment. TABLE 12WILCOXON TWO SAMPLE TEST RESULTS FOR CHANGES IN COUGH SEVERITY WilcoxonTwo-Sample Test Statistic 15492.5 Normal Approximation Z 7.928 One-SidedPr > Z <.0001 Two-Sided Pr > |Z| <.0001 t Approximation One-Sided Pr > Z<.0001 Two-Sided Pr > |Z| <.0001Z includes a continuity correction of 0.5.Summary

From these data it appeared that the treatment was associated with astatistically significant decrease in the use of Ventolin (puffer andnebuliser), Seretide and Flixotide, and that is also associated with asignificant decrease in the severity of coughing, wheezing and shortnessof-breath after four weeks of treatment.

EXAMPLE 23 Vortex Theory

Studies on fluid dynamics have shown discrepancies. One group have shownno transverse force on a vortex due to normal fluid flow, whereasearlier work found a transverse force proportional to normal fluidvelocity u_(n) and normal fluid density r_(n). Applicant has linearizedthe time-independent two-fluid equations about the exact solution for avortex, and found three solutions that are important in the region farfrom the vortex. Uniform fluid flow gives rise to the usual fluid Magnusforce. Uniform normal fluid flow gives rise to no forces in the linearregion, but does not satisfy reasonable boundary conditions at shortdistances. A logarithmically increasing normal fluid flow gives aviscous force. As in classical hydrodynamics this logarithmic increasemust be cut off by non-linear effects at large distances; this gives aviscous force proportional to u_(n)/ln (u_(n)) and a transversecontribution that goes like to u_(n)/ln (u_(n))², even in the absence ofan explicit Iordanskii force. In the limit u_(n) 0, no transverse forceis found, but at non zero u_(n) there are important corrections thatwere not found previously. The Applicant believes that the Magnus forcein a superfluid at non zero temperature is an example of a topologicalrelation for which finite-size corrections may be large.

A vortex threads into limited helical channels: 2-dimensionalhydrodynamics of an ideal liquid. A vortex in an isotropic liquidproduces small amounts of rotons depending on the speed and energy ofthe vortex. Rotons are second generation tachyons formed in oscillatingvortex. This oscillation must be at the fundamental harmonic of thisvortex. This vortex must be greater than 100 mm Radius and at the most2500 mm Radius and velocity to impart 50 to 200 joules per second.$\begin{matrix}{{{Mass},{Energy},\quad{{and}\quad{Speed}\quad{of}\quad a\quad{vortex}\quad{of}\quad{an}}}\quad{{{{Isotropic}\quad{\left. {Fluid} \right.\sim K_{f}^{d}}} + G_{t_{p}^{np}} + {\sum\limits_{t}^{g}m}} = 0}} & {{Equation}\quad 1} \\{{{vortex}\quad{Distortion}\quad{of}\quad{an}\quad{Isotropic}\quad{fluid}}{{{g^{\mu\quad v}p_{u}p_{v}} = 0},{g^{00} = 1},{g^{0i} = {- v_{s}^{i}}},{g^{ik} = {{{- c^{2}}\delta^{ik}} + {v_{s}^{i}v_{s}^{k}}}}}{{ds}^{2} = {{\left( {1 - \frac{v_{s}^{2}}{c^{2}}} \right)\left( {{dt} + \frac{N\quad\kappa\quad d\quad\phi}{2{\pi\left( {c^{2} - v_{s}^{2}} \right)}}} \right)^{2}} - \frac{{dr}^{2}}{c^{2}} - \frac{{dz}^{2}}{c^{2}} - \frac{r^{2}d\quad\phi^{2}}{c^{2} - v_{s}^{2}}}}{\sigma_{\bot} = {{\int_{- \infty}^{+ \infty}{\frac{\mathbb{d}x}{v_{G}}{\int_{- \infty}^{+ \infty}{{\mathbb{d}y}\frac{\partial v_{sy}}{\partial x}}}}} = \frac{N\quad\kappa}{v_{G}}}}} & {{{Equation}\quad 2}\quad} \\{{{{{impact}\quad{energy}\quad{of}\quad{the}\quad{created}\quad{rotons}}\frac{\overset{\_}{a}}{a} + {\frac{\overset{.}{a}}{a}\left( {{x\frac{\overset{.}{b}}{b}} + \frac{\overset{.}{c}}{c}} \right)} - {y\frac{{\overset{.}{a}}^{2}}{a^{2}}} + {2y\frac{\overset{.}{\mathbb{d}}}{\mathbb{d}}\left( {\frac{\overset{.}{a}}{a} - \frac{\overset{.}{\mathbb{d}}}{\mathbb{d}}} \right)} + {x\frac{a^{4} - \left( {b^{2} - c^{2}} \right)^{2}}{2a^{2}b^{2}c^{2}}} + {y\frac{a^{2} + b^{2} - c^{2}}{a^{2}c^{2}}}} = {{\frac{1}{2}\kappa\quad m^{2}\phi^{2}} + {\kappa\frac{\rho}{2}\left( {2 - \lambda} \right)}}},{{\frac{\overset{¨}{b}}{b} + {\frac{\overset{.}{b}}{b}\left( {{x\frac{\overset{.}{a}}{a}} + \frac{\overset{.}{c}}{c}} \right)} - {y\frac{{\overset{.}{b}}^{2}}{b^{2}}} + {2y\frac{\overset{.}{\mathbb{d}}}{\mathbb{d}}\left( {\frac{\overset{.}{b}}{b} - \frac{\overset{.}{\mathbb{d}}}{\mathbb{d}}} \right)} + {x\frac{b^{4} - \left( {a^{2} - c^{2\quad}} \right)^{2}}{2a^{2}b^{2}c^{2}}} + {y\frac{a^{2} + b^{2} - c^{2}}{b^{2}c^{2}}}} = {{\frac{1}{2}\kappa\quad m^{2}\phi^{2}} + {\kappa\frac{\rho}{2}\left( {2 - \lambda} \right)}}},} & {{Equation}\quad 3} \\{\quad{{{{Feidmann}\quad{and}\quad{Einsteing}\quad{Equations}\quad{of}\quad{Vortex}\quad{{Formation}.\left( \frac{\overset{.}{\overset{\sim}{R}}}{\overset{\sim}{R}} \right)^{2}}} = {{\frac{1}{6}\kappa\quad m^{2}\phi^{2}} + {\kappa\frac{\overset{.}{\phi^{2}}}{6}} + {\kappa\frac{\overset{\_}{\rho}}{3}} + \frac{{\overset{\_}{\sigma}}^{2}}{6} - {~~~~~~~~~~~~~~~~}{x\frac{{2a^{2}b^{2}} + {2b^{2}c^{2}} + {2c^{2}a^{2}} - a^{4} - b^{4} - c^{4}}{12a^{2}b^{2}c^{2}}} + {y\frac{1}{3c^{2}}}}},\quad{\frac{\overset{..}{\overset{¨}{\overset{\sim}{R}}}}{\overset{\sim}{R}} = {{\frac{1}{6}\kappa\quad m^{2}\phi^{2}} - {\kappa\frac{\overset{.}{\phi^{2}}}{3}} - {\kappa\frac{\overset{\_}{\rho}}{3}} - \frac{{\overset{\_}{\sigma}}^{2}}{3}}},}} & {\quad{{Equation}\quad 4}} \\{{{The}\quad{velocity}\quad{of}\quad{the}\quad{fluid}\quad{vortex}\quad{line}\quad V_{L}\quad{is}}{{V_{L} = {{h_{1}\left( {V_{s} + V_{I}} \right)} + {h_{2}\hat{t} \times \left( {v_{n} - V_{s} - V_{I}} \right)} + {h_{3}v_{n}}}},{{{where}h_{1}} = \frac{\rho_{s}\kappa\quad D_{0}}{D_{0}^{2} + D^{2}}},{h_{2} = \frac{{\overset{.}{\rho}}_{s}\kappa\quad D}{D_{0}^{2} + D^{2}}},{h_{3} = \frac{D^{2} - {D_{0}D_{t}}}{D_{0}^{2} + D^{2}}},{D_{0} = {{\rho_{s}\kappa} - {D_{t}.}}}}} & {{Equation}\quad 5}\end{matrix}$

D and D_(t) are mutual friction coefficients, r_(s) is the fluiddensity, k is the quantum of circulation, V_(r) is the velocity inducedby the presence of any fluid vortex filaments, and V_(s) is anyexternally applied fluid velocity field.

For a free vortex core, or one bound by a core whose size is much lessthan the mean free path of excitations, then we should take account ofthe effect of the superfluid flow on non-interacting excitations, inaccordance with the discussions.

According to these works the flow of phonons or rotons past a stationaryvortex produces a transverse force equal to Equation 6. $\begin{matrix}{{F_{t} = {{- \frac{\rho_{n}h}{m}}\overset{\Cap}{z} \times u_{c}}},{c_{1} = {{\left\lbrack {{- 1} + \frac{3{K_{0}(a)}}{2{{aK}_{1}(a)}\left( {1 - {\mathbb{i}\alpha}} \right)}} \right\rbrack c_{3}} = {- c_{2}}}},{d_{2} = {{- \frac{3K_{1}^{\prime}(a)}{{{aK}_{1}(a)}\left( {1 - {\mathbb{i}\alpha}} \right)}}c_{3}}},{d_{3} = {{- \frac{3}{{{aK}_{1}(a)}\left( {1 - {\mathbb{i}\alpha}} \right)}}{c_{3}.}}}} & {{Equation}\quad 7}\end{matrix}$

This machine system uses the kinetic energy of isotropic fluids of arange between 40,000 and 80,000 kJ as a function in the production ofthermodynamic rotons and variables such as temperature and pressure hascontinued. Measurements have shown that in contrast to calculations, thekinetic energy of the solution is significantly higher thanexpectations. Based on values taken from the rest before processing.These experiments are been extended and refined. A study of fluiddynamics of vortices has shown that current molecular models provide apoor description of the cross-over region between molecular and atomicbehaviour. More recent research cites more detailed description of thecross-over region. $\begin{matrix}\begin{matrix}{0 = {{{P_{\mu}(j)}{P_{\mu}(j)}{\psi^{2}(j)}} + {m^{2}c^{4}{\psi^{2}(j)}}}} \\{= {{\delta_{\mu\quad v}{P_{\mu}(j)}{\psi(j)}{P_{v}(j)}{\psi(j)}} + {{mc}^{2}{\psi(j)}{mc}^{2}{\psi(j)}}}} \\{= {{\left( {\delta_{\mu\quad v} + \delta_{v\quad\mu}} \right){P_{\mu}(j)}{\psi(j)}{P_{v}(j)}{\psi(j)}\left( {\mu \geq v} \right)} +}} \\{{mc}^{2}{\psi(j)}{mc}^{2}{\psi(j)}} \\{= {{2\delta_{\mu\quad v}{P_{\mu}(j)}{\psi(j)}{P_{v}(j)}{\psi(j)}\left( {\mu \geq v} \right)} +}} \\{{mc}^{2}{\psi(j)}{mc}^{2}{\psi(j)}} \\{= {{2\delta_{\mu\quad v}\delta_{jk}\delta_{jl}{P_{\mu}(k)}{\psi(k)}{P_{v}(l)}{\psi(l)}\left( {\mu \geq v} \right)} +}} \\{\delta_{jk}\delta_{jl}{mc}^{2}{\psi(k)}{mc}^{2}{\psi(l)}}\end{matrix} & {{Equation}\quad 8}\end{matrix}$

The energy of the produced rotons is transferred to the fluid in thesecond stage. This stage used succussion at a rate that is a ratio offrequency x. This frequency x is calculated out by the above formula andRicci Tensors.

1-25. (canceled)
 26. A method of treating a disease in a subject in needof such treatment, comprising the step of administering an effectiveamount of a substance or active agent which comprises one or morecomponents which have been agitated such that a harmonic of between 20to 50 Hz has been produced, with the proviso that the disease is not anairway disorder.
 27. A method according to claim 26, wherein the diseaseis selected from the group consisting of arthritis, osteoporosis,tendonitis, fibromyalgia and traumatic injury.
 28. A method according toclaim 26, wherein the disease is arthritis.
 29. A method according toclaim 26, wherein the subject is a warm-blooded vertebrate.
 30. A methodaccording to claim 29, wherein the warm-blooded vertebrate is a mammalor a bird.
 31. A method according to claim 30, wherein the mammal isselected from the group consisting of humans, dogs, cats, swine,ruminants, primates and horses.
 32. A method according to claim 26,wherein the substance contains an active agent.
 33. A method accordingto claim 32, wherein the active agent possesses therapeutic orprophylactic properties in vivo.
 34. A method according to claim 33,wherein the active agent is a probiotic bacterium, protein, nucleicacid, small molecule or combinations thereof.
 35. A method according toclaim 34, wherein the active agent is a drug, peptide, protein,carbohydrate, nucleoprotein, mucoprotein, lipoprotein, syntheticpolypeptide or protein, or a small molecule linked to a protein,glycoprotein, steroid, nucleic acid, nucleotide, nucleoside,oligonucleotides, gene, lipid, hormone, vitamin, mineral, element orcombinations thereof.
 36. A method according to claim 35, wherein theactive agent further includes an antioxidant, chemotherapeutic agent,steroid, hormone, antibiotic, antiviral, antifungal, antiproliferativeagent, antihistamine, anticoagulant, non-steroidal and steroidalanti-inflammatory compound.
 37. A method according to claim 26, whereinthe harmonic of between 20 to 50 Hz is produced by agitating saidsubstance or active agent.
 38. A substance or active agent produced bythe process of agitation of a starting substance or agent such that aharmonic of between 20 to 50 Hz is produced.
 39. A substance or activeagent useful for treating a disease in a subject in need of suchtreatment, comprising ascorbic acid, magnesium and selenomethionine anda pharmaceutically acceptable carrier, wherein at least one componenthas been agitated such that a harmonic of between 20 to 50 Hz has beenproduced, said ascorbic acid, magnesium and selenomethionine beingcombined in an amount effective to treat said disease.
 40. A process forpreparing a biomorphogenic medicinal composition which comprises: (a)providing a substance or active agent according to claim 38; (b)diluting said substance or active agent using at least one dilution stepby addition of a diluent to produce, following or each dilution step, adiluted preparation having a lower concentration of the substance oractive agent than the concentration of the substance or active agent inthe solution being diluted.
 41. A method of producing a formulation orcomposition of a substance or active agent useful for treating a diseasein a subject in need of such treatment, said formulation or compositioncomprising as components a vitamin, a trace element and probioticbacteria, said method comprising the step of agitating at least one ofsaid components such that a harmonic of between 20 to 50 Hz is produced.42. A device for activating a substance or active agent to render ituseful for treating a disease in a subject, the device comprising acontainer and a agitator, wherein said agitator is capable of producingin the substance or active agent a harmonic of between 20 to 50 Hz. 43.A method of activating a substance or active agent to be effective fortreating a disease in a subject, comprising the steps of (a) introducingsaid substance or active agent into the device of claim 42, and (b)agitating said substance or active agent such that a harmonic of between20 to 50 Hz is produced, thereby rendering said substance or activeagent effective for treating the disease.
 44. A method according toclaim 41, wherein the substance is a foodstuff, a chemical composition,a component of said foodstuff or a component of said chemicalcomposition.
 45. A method according to claim 41, wherein the activeagent is a therapeutically-active or prophylactically-active chemicalcomposition, herbicide, pesticide, or nutrient.
 46. A method accordingto claim 41, wherein the active agent is a protein, a nucleic acid, achemical compound, or probiotic bacteria.
 47. The method of claim 46wherein said chemical compound is a vitamin, a mineral, an antibiotic asteroid or a decongestant agent.
 48. A method according to claim 43,wherein the active agent is an antioxidant, a chemotherapeutic agent, asteroid, a retinoid, a hormone, an antibiotic, an antiviral, anantifungal, an antiproliferative, an antihistamine, an anticoagulant, anantiphotoaging agent, a melanotropic peptide, or a steroidal ornonsteroidal anti-inflammatory compound.
 49. A method according to claim43, wherein the substance or active agent is a herbicide is selectedfrom the group consisting of 2,4-dichlorophenoxyacetic acid (2,4-D;WEEDAR™); 4-(2,4-dichlorophenoxy)butyric acid (2,4-DB);3′,4′-dichloropropionanilide (DCPA; (Dacthal™); disodium methylarsonate(DSMA; ARSONATE™); S-ethyl dipropylthiocarbamate (EPTC; EPTAM™.ERADICANE™); 4-chloro-2-methylphenoxy)acetic acid (MCPA; (RHONOX™);4-(4-chloro-2-methylphenoxy)butanoic acid (MCPB; THISTROL™); monosodiummethylarsonate (MSMA; ANSAR™); acetochlor (HARNESS™); acetochlor(SURPASS™); acifluorfen (BLAZER™); alachlor (LASSO™); ametryn (EVIK™);amitrole (AMITROL-T™); asulam (ASULOX™); atrazine (AATREX™); azafenidin(MILESTONE™); benefin (BALAN™); bensulfuron (LONDAX™); bensulide(PREFAR™); bentazon (BASAGRAN™); bromacil (HYVAR-X™); bromoxynil(BUCTRIL™); butylate (SUTAN™); carfentrazone-ethyl (AIM™); chloramben(AMIBEN™); chlorimuron-ethyl (CLASSIC™); chlorpropham(FURLOE™);chlorsulfuron (GLEAN™); clethodim (PRISM™); clethodim(SELECT™); clomazone (COMMAND™); clopyralid (STINGER™); cloransulam(FIRST-RATE™); cyanazine (BLADEX™); cycloate (RO-NEET™); cycloxydim(FOCUS™); desmedipham (BETANEX™); dicamba (BANVEL™); dichlobenil(CASORON™); diclofop (HOELON™); diethatyl (ANTOR™); difenzoquat(AVENGE™); diflufenzopyr (DISTINCT™); dimethenamid (FRONTIER™); diquat(DIQUAT™); diuron (KARMEX™); endothall (DESICATE™); ethalfluralin(CURBIT™); ethalfluralin (SONALAN™); ethametsulfuron (MUSTER™);ethofumesate (NORTRON™); fenoxaprop-ethyl (BUGLE™); fenoxaprop-ethyl(OPTION II™); fluazifop-P (FUSILADE DX™); flucarbazone-sodium (MKH6562™); flufenacet (AXIOM™); flumetsulam (BROADSTRIKE™); flumiclorac(RESOURCE™); flumioxazin (V-53482™); fluometuron (COTORAN™); fluroxypyr(STARANE™); fomesafen (FLEXSTAR™); fomesafen (REFLEX™); glufosinate(RELY™); glyphosate (ROUNDUP™); halosulfuron (PERMIT, SEMPRA™);haloxyfop (GALANT™); hexazinone (VELPAR™); imazameth (CADRE™);imazamethabenz (ASSERT™); imazamox (RAPTOR™); imazaquin (SCEPTER™);imazethapyr (PURSUIT™); isoxaben (GALLERY™); isoxaflutole (BALANCE™);lactofen (COBRA™); linuron (LOROX™); methazole (PROBE™); metolachlor(DUAL™); metribuzin (LEXONE™); metribuzin (SENCOR™); metsulfuron(ALLY™); molinate (ORDRAN™); napropamide (DEVRINOL™); naptalam(ALANAP™); nicosulfuron (ACCENT™); norflurazon (SOLICAM™); oryzalin(SURFLAN™); oxadiazon (RONSTAR™); oxasulfuron (DYNAM™); oxyfluorfen(GOAL™); paraquat (GRAMOXONE EXTRA™); pebulate (TILLAM™); pelargonicacid (SCYTHE™); pendimethalin (PENTAGON™); pendimethalin (PROWL™);phenmedipham (SPIN-AID™); picloram (TORDON™); primisulfuron (BEACON™);prodiamine (BARRICADE™); prometryn (CAPAROL™); pronamide (KERB™);propachlor (RAMROD™); propanil (STAMPEDE™); prosulfuron (PEAK™);pyrazon(PYRAMIN™); pyridate (LENTAGRANN™); pyridate (TOUGH™); pyrithiobac(STAPLE™); quinclorac (FACET™); quizalofop (ASSURE™); rimsulfuron(MATRIX, SHADEOUT™); sethoxydim (POAST™); siduron (TUPERSAN™); simazine(PRINCEP™); sulfentrazone (AUTHORITY™); sulfometuron (OUST™); sulfosate(TOUCHDOWN™); sulfosulfuron (MON™); tebuthiuron (SPIKE™); terbacil(SINBAR™); thiazopyr (VISOR, MANDATE™); thifensulfuron (PINNACLE™);thiobencarb (BOLERO™); tralkoxydim (ACHEIVE™); triallate (FAR-GO™);triasulfuron (AMBER™); tribenuron (EXPRESS™); triclopyr (GARLON™);triclopyr (GRANDSTAND™); trifluralin (TREFLAN™); triflusulfuron(UPBEET™) and vemolate (VERNAM™).
 50. A method according to claim 45,wherein the active agent is a pesticide selected from the groupconsisting of 1,2-dichloropropane; 1-naphthaleneacetamide;1-naphthylacetic acid; 2,4,5-trichlorophenoxyacetic (2,4,5-T) acid; a2,4,5-T amine salt; a 2,4,5-T ester; 4-2,4-dichlorophenoxybutyric acid(2,4-DB); 2,4-DB butoxyethyl ester; 2,4-DB dimethylamine salt(2,4-DB-DMAS); ABAMECTIN™; ACEPHATE™; ACIFLUOREN™; ACIFLUORFEN™;ACROLEIN™; ALACHLOR™; ALDICARB™; ALDOXYCARB™; ALDRIN™; AMETRYN™;AMINOCARB™; AMITRAZ™; AMITROLE™; ANCYMIDOL™; ANILAZINE™; arsenic acid;Asulam-Na; ATRAZINE™; AZIMSULFURON™; AZINPHOS-ME™; BARBAN™; BENALAXYL™;BENDIOCARB™; BENEFIN™; BENODANIL™; BENOMYL™; BENSULFURON ME™;BENSULIDE™; BENTAZON™; BIFENOX™; BIFENTHRIN™; BROMACIL™; Bromoxynilbutyrate; BROMOXYNIL™; OCTANOATE™; BUTACHLOR™; Butylate; CAPTAFOL™;CAPTAN™; CARBARYL™; CARBENDAZIM™; CARBOFURAN™; Carbon Disulfide;CARBOPHENOTHION™; CARBOXIN™; CDAA; CHLORAMBEN™; CHLORBROMURON™;CHLORDANE™; chlordimeform; chlordimeform HCl; CHLORETHOXYFOS™;CHLORIDAZON™; CHLOROBENZILATE™; CHLORONEB™; CHLOROPICRIN™;CHLOROTHALONIL™; CHLOROXURON™; CHLORPROPHAM™; CHLORPYRIFOS™;chlorpyrifos-methyl; CHLORSULFURON™; CHLOZOLINATE™; CINMETHYLIN™;CLOFENTEZINE™; CLOMAZONE™; CLOPYRALID™; CRYOLITE™; CYANAZINE™;CYCLOATE™; CYFLUTHRIN™; CYHALOTHRIN™; CYHEXATIN™; CYMOXANIL™;CYPERMETHRIN™; CYROMAZINE™; DAMINOZIDE™; DAZOMET™; DBCP™; DCNADICLORAN™; DDD™; DDE™; DDT™; DEMETON™; DESMEDIPHAM™; DI-ALLATE™;DIAZINON™; DICAMBA™; DICHLOBENIL™; DICHLONE™; DICHLORMID;DICHLOROPROPENE; DICHLORPROP; DICHLORVOS; DICLOFOP-ME; DICOFOL;DICROTOPHOS; DIELDRIN; DIENOCHLOR; DIFLUBENZURON; DIMETHIPIN;DIMETHIRIMOL; DIMETHOATE; DIMETHYLARSINIC ACID; DINITRAMINE; DINOCAP;DINOSEB; DIOXACARB; DIPROPETRYN; DIQUAT DIBROMIDE; DISULFOTON; DIURON;DNOC; DODINE ACETATE SALT; DSMA; ENDOSULFAN; ENDOTHALL; ENDRIN; EPN;EPTC; ESFENVALERATE; ETHALFLURALIN; ETHEPHON; ETHOFUMESATE; ETHOPROP;ETHYLENE DIBROMIDE; ETRIDIAZOLE; FENAMINOSULF; FENAMIPHOS; FENARIMOL;FENBUTATIN OXIDE; FENFURAM; FENITROTHION; FENOPROP; FENOXAPROP-ET;FENOXYCARB; FENPROPATHRIN; FENSULFOTHION; FENTHION; FENURON;FENVALERATE; FERBAM; FLUAZIFOP-BUTYL; FLUAZIFOP-P-BUTYL; FLUCHLORALIN;FLUCYTHRINATE; FLUMETRALIN; FLUMETSULAM; FLUOMETURON; FLUPYRSULFURONMETHYL; FLURIDONE; FLUSILAZOLE; FLUSILAZOLEHTM; FLUSILAZOLE; FOMESAFEN;FONOFOS; FORMETANATE HCL; FOSAMINE AMMONIUM; FOSAMINE AMMONIUM; FOSETYLALUMINUM; GLUFOSINATE-AMMONIUM; GLYPHOSATE; HALOXYFOP-METHYL;HEPTACHLOR; HEXACHLOROBENZENE; HEXAZINONE; HEXAZINONEhtm; HEXAZINONEtxt;HYDRAMETHYLNON; IMAZALIL;IMAZAPYR ACID; IMAZAQUIN ACID; IMAZETHAPYR;IPRODIONE; ISAZOFOS; ISOFENPHOS; ISOPROPALIN; ISOXABEN; LACTOFEN;LENACIL; LENACILhtm; LENACILtxt; LINDANE; LINURON; MALATHION; maleichydrazide acid; MANCOZEB; MANEB; MCPA; MCPB; MECOPROP; mefluidide;MEPIQUAT chloride; METALAXYL; metaldehyde; methamidophos; metham sodium;methazole; methiocarb; methomyl; METHOXYCHLOR™; methyl bromide; methylisothiocyanate; methyl parathion; METIPAM™; METOLACHLOR™; METRIBUZIN™;METSULFURON ME™; MEVINPHOS™; MEXACARBATE™; MIREX™; MOLINATE™;MONOCROTOPHOS™; MONOLINURON™; MONURON™; MSMA™; MYCLOBUTANIL™; NALED™;naphthalene; napropamide; naptalam sodium salt; NEBURON™; NICOSULFURON™;NITRAPYRIN™; NITROFEN™; NORFLURAZON™; ORYZALIN™; OXADIAZON™; OXAMYL™;OXYCARBOXIN™; OXYDEMETON-ME; OXYFLUORFEN; PACLOBUTRAZOL™; PARAQUATDICHLORIDE™; PARATHION™; PEBULATE™; PENDIMETHALIN™; pentachlorophenol;perfluidone; perimiphos-ethyl; PERMETHRIN™; PHENMEDIPHAM™; PHENTHOATE™;PHORATE™; PHOSALONE™; PHOSMET™; PHOSPHAMIDON™; PICLORAM™; PIPERALIN™;PIRIMICARB™; pirimiphos-methyl; pirimiphos-ethyl; primisulfuron-methyl;prochloraz; procymidone; prodiamine; profenofos; profluralin;PROMECARB™; PROMETON; PROMETRYN; PROPACHLOR; PROPAMOCARB HCl; PROPANIL;PROPARGITE™; PROPAZINE™; PROPHAM; PROPICONAZOLE; PROPOXUR; PROPYZAMIDE™;PYRETHRINS™; PYRITHIOBAC SODIUM; QUINOMETHIONATE™; QUINTOZENE;QUIZALOFOP-ET; RESMETHRIN; RIMSULFURON; ROTENONE™; SECBUMETON;SETHOXYDIM; SIDURON™; SIMAZINE™; SIMETRYN™; sodium chlorate;sulfometuron-Me; sulprofos; TAU-FLUVALINATE™; TCA-sodium; TEBUTHIURON;TEMEPHOS; TERBACIL; TERBUFOS; TERBUTRYN; TETRACHLORVINPHOS™;THIABENDAZOLE™; THIDIAZURON™; THIOBENCARB™; THIODICARB™;THIOPHANATE-ME™; THIRAM™; TOLCLOFOS-METHYL™; TOXAPHENE™; TRALOMETHRIN™;TRIADIMEFON™; TRIADIMENOL; TRIALLATE™; TRIASULFURON™; TRIBUFOS™;TRICHLORFON™; TRICHLORONAT™; TRICLOPYR™; TRICYCLAZOLE™; TRIDEPHANE™;TRIFLUMIZOLE™; TRIFLURALW™; TRIFLUSULFURON METHYL™; TRIFORINE™;TRIMETHACARB™; VINCLOZOLD™; ZINEB™ and ZIRAM™.
 51. A method according toclaim 44, wherein the foodstuff is a baked good; a breakfast cereal; acandy; a chewing gum; a chocolate product; a gelatin dessert; a dairyproduct; a vegetable oil, a beverage; a non-dairy shortening product; anon-dairy whitener; a whipping agent; an artificial whipped cream; acured meat; potato chips or another snack food; processed egg whites; ajelly; an infant formula; a salad dressing or a sandwich spread.